

Dataset Integrity Check for Chronic Renal Insufficiency Cohort (CRIC): DSIC 1 --- Baseline Analysis Dataset (MS004)

As a partial check of the integrity of the CRIC datasets archived in the NIDDK data repository, a set of tabulations was performed to verify that published results from the CRIC study can be reproduced using the archived datasets. Analyses were performed to duplicate published results for two CRIC datasets. The present Dataset Integrity Check (DSIC) reports results for the baseline analysis dataset (MS004). This dataset supports findings reported in 2009 by Lash et al. in an article in the *Clinical Journal of the American Society of Nephrology*.¹ Initial analyses of these data revealed that there were a few inaccuracies in the published tables. The DCC provided a new set of corrected tables which have been used in this Dataset Integrity Check. The “published” values shown in our tables are the corrected values provided by the DCC not the originally published values. We replicate the two major tables from the baseline analysis: Table 3, “Baseline demographic and clinical characteristics of participants”; and Table 4, “Baseline characteristics by eGFR level.”)

Purpose. The intent of this dataset integrity check is to provide confidence that the dataset distributed by the NIDDK repository is a true copy of the study data. Our intent is not to assess the integrity of the statistical analyses reported by study investigators. As with all statistical analyses of complex datasets, complete replication of a set of statistical results should not be expected on a first (or second) exercise in secondary analysis. This occurs for a number of reasons including differences in the handling of missing data, restrictions on cases included in samples for a particular analysis, software coding used to define

¹ Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A, Robinson N, Teal V, Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. *Clin J Am Soc Nephrol*. 2009 Aug;4(8):1302-11.

complex variables, etc. Experience suggests that most discrepancies can ordinarily be resolved by consultation with the study DCC, however this process is labor-intensive for both DCC and Repository staff. It is thus not our policy to resolve every discrepancy that is observed in a dataset integrity check. Thus, we do not attempt to resolve minor or inconsequential discrepancies with published results or discrepancies that involve complex analyses unless staff of the NIDDK Repository suspect that the observed discrepancy suggests that the dataset may have been corrupted in storage, transmission, or processing by repository staff.

Datasets. The dataset used for these analyses was ms004_analytical_data_final.sas7bdat received from the DCC (with date stamp of 7-19-2011). This SAS dataset was converted to Stata format using Stat/Transfer and output as a Stata data file ms004_analytical_data_final.dta (with date stamp of 8-9-2011). The SAS format file(formats.sas7bcat) provided by the DCC was processed by Stat/Transfer to construct value labels.

Baseline Demographic Characteristics. Table 1 (published table 3) displays more than 30 baseline sociodemographic and medical characteristics of respondents for: (1) the entire cohort, (2) the subcohort with iGFR, and (3 & 4) subcohorts with and without diabetes. There is perfect agreement between both the basic values (Ns, means and SDs for metric variables; Ns and percent distributions for categorical variables) and p-values provided by the DCC and those calculated from the archived dataset.

Baseline Demographic Characteristics by eGFR. Table 2 (published table 4) displays the same 30+ baseline sociodemographic and medical characteristics of respondents at 5 levels of eGFR (estimated glomerular filtration rate). There are no noteworthy discrepancies between the values calculated from the archived dataset and those reported in the DCC's tables. Some substantively unimportant discrepancies in p-values were found.²

Conclusion. Our results fully replicate the two major baseline tables provided by the DCC. As noted previously, these tables corrected a small number of errors in the published article.

² The DCC has noted that “[for this table] we treated eGFR as a continuous variable in calculating the p values. That is, the p value was from a linear regression where eGFR is the dependent variable and the row variables as independent variables. So the p values for categorical row variables is from ANOVA where the dependent variable is eGFR and row variable defining the groups. For continuous variables the p values are the same as the p value in correlation analysis between eGFR and the continuous row variable. This might explain the [observed] differences.” (Email from Dawei Xie, September 15, 2011)

TABLE 1: Comparison of results provided by DCC for CRIC published Table 3 and results calculated from analysis dataset MS004. Calculated values are shown in italics underneath DCC's reported values.(a)

Variable	Cohort	Subcohort with iGFR	Diabetes	No Diabetes	P Diabetes vs. No Diabetes
n	3612	1288	1685	1927	
	<i>3612</i>	<i>1288</i>	<i>1685</i>	<i>1927</i>	
Age (yr; mean ±SD)	58.2 +/- 11.0	56.1 +/- 12.5	59.5 +/- 9.8	57.1 +/- 11.8	0.0001
	<i>58.2 +/- 11.0</i>	<i>56.1 +/- 12.5</i>	<i>59.5 +/- 9.8</i>	<i>57.1 +/- 11.8</i>	<i>< 0.0001</i>
Gender (n [%])					0.2516
Male	1959 (54%)	713 (55%)	931 (55%)	1028 (53%)	<i>0.252</i>
	<i>1959 (54%)</i>	<i>713 (55%)</i>	<i>931 (55%)</i>	<i>1028 (53%)</i>	
Female	1653 (46%)	575 (45%)	754 (45%)	899 (47%)	
	<i>1653 (46%)</i>	<i>575 (45%)</i>	<i>754 (45%)</i>	<i>899 (47%)</i>	
Race/Ethnicity group (n [%])					0.0001
Non-Hispanic White	1638 (45%)	588 (46%)	649 (39%)	989 (51%)	<i><0.001</i>
	<i>1638 (45%)</i>	<i>588 (46%)</i>	<i>649 (39%)</i>	<i>989 (51%)</i>	
Non-Hispanic Black /African American	1651 (46%)	532 (41%)	849 (50%)	802 (42%)	
	<i>1651 (46%)</i>	<i>532 (41%)</i>	<i>849 (50%)</i>	<i>802 (42%)</i>	
Hispanic	169 (5%)	69 (5%)	111 (7%)	58 (3%)	
	<i>169 (5%)</i>	<i>69 (5%)</i>	<i>111 (7%)</i>	<i>58 (3%)</i>	
Other ^b	154 (4%)	99 (8%)	76 (5%)	78 (4%)	
	<i>154 (4%)</i>	<i>99 (8%)</i>	<i>76 (5%)</i>	<i>78 (4%)</i>	
Annual Household Income (n [%])					0.0001
\$20,000 or under	1009 (28%)	297 (23%)	565 (34%)	444 (23%)	<i><0.001</i>
	<i>1009 (28%)</i>	<i>297 (23%)</i>	<i>565 (34%)</i>	<i>444 (23%)</i>	
\$20,001 - \$50,000	906 (25%)	338 (26%)	432 (26%)	474 (25%)	
	<i>906 (25%)</i>	<i>338 (26%)</i>	<i>432 (26%)</i>	<i>474 (25%)</i>	
\$50,001 - \$100,000	725 (20%)	306 (24%)	281 (17%)	444 (23%)	
	<i>725 (20%)</i>	<i>306 (24%)</i>	<i>281 (17%)</i>	<i>444 (23%)</i>	
More than \$100,000	389 (11%)	154 (12%)	136 (8%)	253 (13%)	
	<i>389 (11%)</i>	<i>154 (12%)</i>	<i>136 (8%)</i>	<i>253 (13%)</i>	
No Response	583 (16%)	193 (15%)	271 (16%)	312 (16%)	
	<i>583 (16%)</i>	<i>193 (15%)</i>	<i>271 (16%)</i>	<i>312 (16%)</i>	

Variable	Cohort	Subcohort with iGFR	Diabetes	No Diabetes	P Diabetes vs. No Diabetes
Educational attainment (n [%])					0.0001
<7th grade	60 (2%)	16 (1%)	41 (2%)	19 (1%)	<0.001
	60 (2%)	16 (1%)	41 (2%)	19 (1%)	
7th to 12th grade	545 (15%)	153 (12%)	319 (19%)	226 (12%)	
	545 (15%)	153 (12%)	319 (19%)	226 (12%)	
High school diploma	695 (19%)	239 (19%)	339 (20%)	356 (18%)	
	695 (19%)	239 (19%)	339 (20%)	356 (18%)	
Vocational degree	184 (5%)	64 (5%)	98 (6%)	86 (4%)	
	184 (5%)	64 (5%)	98 (6%)	86 (4%)	
Some college	921 (26%)	319 (25%)	440 (26%)	481 (25%)	
	921 (26%)	319 (25%)	440 (26%)	481 (25%)	
College graduate	696 (19%)	298 (23%)	281 (17%)	415 (22%)	
	696 (19%)	298 (23%)	281 (17%)	415 (22%)	
Graduate degree	510 (14%)	198 (15%)	167 (10%)	343 (18%)	
	510 (14%)	198 (15%)	167 (10%)	343 (18%)	
Tobacco use (n [%])					
Current Smoker	494 (14%)	152 (12%)	212 (13%)	282 (15%)	0.0733
	494 (14%)	152 (12%)	212 (13%)	282 (15%)	0.073
>100 Cigarettes during lifetime	2019 (56%)	667 (52%)	983 (58%)	1036 (54%)	0.0057
	2019 (56%)	667 (52%)	983 (58%)	1036 (54%)	0.006
Medical History (n [%])					
hypertension	3094 (86%)	1091 (85%)	1552 (92%)	1542 (80%)	0.0001
	3094 (86%)	1091 (85%)	1552 (92%)	1542 (80%)	<0.001
MI or coronary revascularization	810 (22%)	225 (17%)	493 (29%)	317 (16%)	0.0001
	810 (22%)	225 (17%)	493 (29%)	317 (16%)	<0.001

Variable	Cohort	Subcohort with iGFR	Diabetes	No Diabetes	P Diabetes vs. No Diabetes
Chronic heart failure	357 (10%)	86 (7%)	245 (15%)	112 (6%)	0.0001
	357 (10%)	86 (7%)	245 (15%)	112 (6%)	<0.001
PAD	250 (7%)	80 (6%)	181 (11%)	69 (4%)	0.0001
	250 (7%)	80 (6%)	181 (11%)	69 (4%)	<0.001
BP variables					
SBP(mmHg; mean \pm SD)	127.7 +/- 21.9	127.8 +/- 21.3	132.4 +/- 22.5	123.6 +/- 20.5	0.0001
	127.7 +/- 21.9	127.8 +/- 21.3	132.4 +/- 22.5	123.6 +/- 20.5	<0.001
DBP (mmHg; mean \pm SD)	71.4 +/- 12.8	72.4 +/- 12.7	69.4 +/- 12.8	73.1 +/- 12.6	<0.001
	71.4 +/- 12.8	72.4 +/- 12.7	69.4 +/- 12.8	73.1 +/- 12.6	<0.001
MAP (mmHg; mean \pm SD)	90.2 +/- 13.8	90.9 +/- 13.2	90.4 +/- 13.9	89.9 +/- 13.6	0.3113
	90.2 +/- 13.8	90.9 +/- 13.2	90.4 +/- 13.9	89.9 +/- 13.6	0.3113
BP>130/80 mmHg	1686 (47%)	626 (49%)	882 (53%)	804 (42%)	0.0001
	1686 (47%)	626 (49%)	882 (53%)	804 (42%)	<0.001
Weight (kg; mean \pmSD)	92.0 +/- 23.7	89.9 +/- 21.2	97.7 +/- 24.2	87.1 +/- 22.1	0.0001
	92.0 +/- 23.7	89.9 +/- 21.2	97.7 +/- 24.2	87.1 +/- 22.1	<0.001
BMI (kg/m²; mean \pmSD)	32.1 +/- 7.9	31.3 +/- 7.0	34.1 +/- 8.2	30.3 +/- 7.2	0.0001
	32.1 +/- 7.9	31.3 +/- 7.0	34.1 +/- 8.2	30.3 +/- 7.2	<0.001
BMI (kg/m²; n [%])					0.0001
<25.0	607 (17%)	234 (18%)	179 (11%)	428 (22%)	<0.001
	607 (17%)	234 (18%)	179 (11%)	428 (22%)	
25.0-29.9	1018 (28%)	381 (30%)	388 (23%)	630 (33%)	
	1018 (28%)	381 (30%)	388 (23%)	630 (33%)	
>=30.0	1987 (55%)	673 (52%)	1118 (66%)	869 (45%)	
	1987 (55%)	673 (52%)	1118 (66%)	869 (45%)	

Variable	Cohort	Subcohort with iGFR	Diabetes	No Diabetes	P Diabetes vs. No Diabetes
ABI<0.9 (n [%])	584 (16%)	194 (15%)	371 (23%)	213 (11%)	0.0001
	584 (16%)	194 (15%)	371 (23%)	213 (11%)	<0.001
Kidney Function Measures					
Adjusted serum creatinine (mg/dl; mean ±SD)	1.73 +/- 0.57	1.68 +/- 0.56	1.80 +/- 0.56	1.67 +/- 0.57	0.0001
	1.73 +/- 0.57	1.68 +/- 0.56	1.80 +/- 0.56	1.67 +/- 0.57	<0.0001
eGFR (mL/min/1.73m ² ; mean ±SD)	43.4 +/- 13.5	45.2 +/- 14.1	41.4 +/- 12.9	45.1 +/- 13.8	0.0001
	43.4 +/- 13.5	45.2 +/- 14.1	41.4 +/- 12.9	45.1 +/- 13.8	<0.0001
eGFR (mL/min/1.73m ² ; n [%])					0.0001
<15	3 (0%)	2 (0%)	1 (0%)	2 (0%)	<0.001
	3 (0%)	2 (0%)	1 (0%)	2 (0%)	
15-29	664 (18%)	206 (16%)	351 (21%)	313 (16%)	
	664 (18%)	206 (16%)	351 (21%)	313 (16%)	
30-59	2532 (70%)	887 (69%)	1197 (71%)	1335 (70%)	
	2532 (70%)	887 (69%)	1197 (71%)	1335 (70%)	
60-89	389 (11%)	187 (15%)	126 (8%)	263 (14%)	
	389 (11%)	187 (15%)	126 (8%)	263 (14%)	
>90	8 (0%)	4 (0%)	4 (0%)	4 (0%)	
	8 (0%)	4 (0%)	4 (0%)	4 (0%)	
Urine Protein/24 h (g; median [IQR])	0.17 (0.07 to 0.81)	0.18 (0.07 to 0.90)	0.32 (0.09 to 1.49)	0.11 (0.06 to 0.43)	0.0001
	0.17 (0.07 to 0.81)	0.18 (0.07 to 0.90)	0.32 (0.09 to 1.49)	0.11 (0.06 to 0.43)	<0.001
ACEI or ARB therapy (n [%])	2462 (68%)	880 (68%)	1336 (79%)	1126 (58%)	0.0001
	2462 (68%)	880 (68%)	1336 (79%)	1126 (58%)	<0.001
Lipoproteins (mg/dl; mean ±SD)					
Total cholesterol	183.1 +/- 44.5	183.6 +/- 47.0	177.0 +/- 47.1	188.4 +/- 41.5	0.0001
	183.1 +/- 44.5	183.6 +/- 47.0	177.0 +/- 47.1	188.4 +/- 41.5	<0.001
LDL cholesterol	102.6 +/- 35.3	103.4 +/- 36.5	96.4 +/- 35.4	108.1 +/- 34.2	0.0001
	102.6 +/- 35.3	103.4 +/- 36.5	96.4 +/- 35.4	108.1 +/- 34.2	<0.001

Variable	Cohort	Subcohort with iGFR	Diabetes	No Diabetes	P Diabetes vs. No Diabetes
HDL cholesterol	48.1 +/- 15.6	47.5 +/- 15.7	45.7 +/- 13.9	50.1 +/- 16.7	0.0001
	48.1 +/- 15.6	47.5 +/- 15.7	45.7 +/- 13.9	50.1 +/- 16.7	<0.001
Triglycerides	153.7 +/- 115.2	151.5 +/- 111.9	166.0 +/- 129.8	142.9 +/- 99.3	0.0001
	153.7 +/- 115.2	151.5 +/- 111.9	166.0 +/- 129.8	142.9 +/- 99.3	<0.001
Hemoglobin (g/dl; mean ±SD)	12.7 +/- 1.8	12.6 +/- 1.7	12.1 +/- 1.7	13.2 +/- 1.7	0.0001
	12.7 +/- 1.8	12.6 +/- 1.7	12.1 +/- 1.7	13.2 +/- 1.7	<0.001
Serum calcium (mg/dl; mean ±SD)	9.2 +/- 0.5	9.2 +/- 0.5	9.1 +/- 0.5	9.2 +/- 0.5	0.0001
	9.2 +/- 0.5	9.2 +/- 0.5	9.1 +/- 0.5	9.2 +/- 0.5	<0.001
Serum phosphate (mg/dl; mean ±SD)	3.7 +/- 0.7	3.7 +/- 0.7	3.9 +/- 0.7	3.5 +/- 0.6	0.0001
	3.7 +/- 0.7	3.7 +/- 0.7	3.9 +/- 0.7	3.5 +/- 0.6	<0.001
Total PTH (pg/ml; median [IQR])	53.0 (34.0 to 88.0)	52.9 (34.0 to 85.0)	60.0 (37.1 to 102.4)	48.5 (32.5 to 78.0)	0.0001
	53.0 (34.0 to 88.0)	52.9 (34.0 to 85.0)	60.0 (37.1 to 102.4)	48.5 (32.5 to 78.0)	<0.001
Blood glucose (mg/dl; median [IQR])	97.0 (86.0 to 124.0)	97.0 (86.0 to 121.0)	127.0 (100.0 to 163.0)	90.0 (84.0 to 98.0)	0.0001
	97.0 (86.0 to 124.0)	97.0 (86.0 to 121.0)	127.0 (100.0 to 163.0)	90.0 (84.0 to 98.0)	<0.001
Glycosylated hemoglobin (%; mean ±SD)	6.6 +/- 1.6	6.5 +/- 1.6	7.7 +/- 1.7	5.7 +/- 0.5	0.0001
	6.6 +/- 1.6	6.5 +/- 1.6	7.7 +/- 1.7	5.7 +/- 0.5	<0.001

(a) ABI, ankle-brachial index; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; DBP, diastolic BP; eGFR, estimated GFR; iPTH, intact parathyroid hormone; IQR, interquartile range; MAP, mean arterial pressure; MI, myocardial infarction; PAD, peripheral arterial disease; SBP, systolic BP.

(b) Includes Asian/Pacific Islander and Native American individuals.

TABLE 2: Comparison of results provided by DCC for CRIC published Table 4 and results calculated from analysis dataset MS004. Calculated values are shown in italics underneath DCC's reported values.

VARIABLE	eGFR (ml/min per 1.73 m2)					P
	<30	30-<40	40-<50	50-<60	>=60	
n	667	844	968	720	397	
Age (yr; mean ±SD)	58.7 +/- 11.2	59.6 +/- 11.0	60.0 +/- 10.4	57.7 +/- 10.1	51.5 +/- 11.0	0.0001
	<i>58.7 +/- 11.2</i>	<i>59.6 +/- 11.0</i>	<i>60.0 +/- 10.4</i>	<i>57.7 +/- 10.1</i>	<i>51.5 +/- 11.0</i>	<i><0.0001</i>
Gender (n [%])						0.0001
Male	311 (47%)	440 (52%)	568 (59%)	406 (56%)	226 (57%)	<i><0.0001</i>
	<i>311 (47%)</i>	<i>440 (52%)</i>	<i>568 (59%)</i>	<i>406 (56%)</i>	<i>226 (57%)</i>	
Female	356 (53%)	404 (48%)	400 (41%)	314 (44%)	171 (43%)	
	<i>356 (53%)</i>	<i>404 (48%)</i>	<i>400 (41%)</i>	<i>314 (44%)</i>	<i>171 (43%)</i>	
Race/Ethnicity group (n [%])						0.0012
Non-Hispanic White	277 (42%)	386 (46%)	461 (48%)	348 (48%)	160 (40%)	<i><0.001</i>
	<i>277 (42%)</i>	<i>386 (46%)</i>	<i>461 (48%)</i>	<i>348 (48%)</i>	<i>160 (40%)</i>	
Non-Hispanic Black /African American	303 (45%)	387 (46%)	430 (44%)	319 (44%)	202 (51%)	
	<i>303 (45%)</i>	<i>387 (46%)</i>	<i>430 (44%)</i>	<i>319 (44%)</i>	<i>202 (51%)</i>	
Hispanic	55 (8%)	43 (5%)	32 (3%)	21 (3%)	18 (5%)	
	<i>55 (8%)</i>	<i>43 (5%)</i>	<i>32 (3%)</i>	<i>21 (3%)</i>	<i>18 (5%)</i>	
Other ^a	32 (5%)	28 (3%)	45 (5%)	32 (4%)	17 (4%)	
	<i>32 (5%)</i>	<i>28 (3%)</i>	<i>45 (5%)</i>	<i>32 (4%)</i>	<i>17 (4%)</i>	

VARIABLE	eGFR (ml/min per 1.73 m2)					P
	<30	30-<40	40-<50	50-<60	>=60	
Annual Household Income (n [%])						0.0001
\$20,000 or under	249 (37%)	292 (35%)	232 (24%)	155 (22%)	72 (18%)	<0.001
	249 (37%)	292 (35%)	232 (24%)	155 (22%)	72 (18%)	
\$20,001 - \$50,000	179 (27%)	199 (24%)	267 (28%)	162 (23%)	96 (24%)	
	179 (27%)	199 (24%)	267 (28%)	162 (23%)	96 (24%)	
\$50,001 - \$100,000	108 (16%)	150 (18%)	187 (19%)	171 (24%)	108 (27%)	
	108 (16%)	150 (18%)	187 (19%)	171 (24%)	108 (27%)	
More than \$100,000	38 (6%)	69 (8%)	117 (12%)	115 (16%)	49 (12%)	
	38 (6%)	69 (8%)	117 (12%)	115 (16%)	49 (12%)	
No Response	93 (14%)	134 (16%)	165 (17%)	117 (16%)	72 (18%)	
	93 (14%)	134 (16%)	165 (17%)	117 (16%)	72 (18%)	
Educational attainment (n [%])						0.0001
<7th grade	27 (4%)	15 (2%)	10 (1%)	4 (1%)	4 (1%)	<0.001
	27 (4%)	15 (2%)	10 (1%)	4 (1%)	4 (1%)	
7th to 12th grade	126 (19%)	160 (19%)	143 (15%)	82 (11%)	27 (7%)	
	126 (19%)	160 (19%)	143 (15%)	82 (11%)	27 (7%)	
High school diploma	145 (22%)	177 (21%)	189 (20%)	112 (16%)	69 (17%)	
	145 (22%)	177 (21%)	189 (20%)	112 (16%)	69 (17%)	
Vocational degree	36 (5%)	38 (5%)	48 (5%)	36 (5%)	26 (7%)	
	36 (5%)	38 (5%)	48 (5%)	36 (5%)	26 (7%)	
Some college	162 (24%)	224 (27%)	228 (24%)	192 (27%)	112 (28%)	
	162 (24%)	224 (27%)	228 (24%)	192 (27%)	112 (28%)	
College graduate	106 (16%)	146 (17%)	188 (19%)	172 (24%)	82 (21%)	
	106 (16%)	146 (17%)	188 (19%)	172 (24%)	82 (21%)	
Graduate degree	65 (10%)	84 (10%)	162 (17%)	122 (17%)	76 (19%)	
	65 (10%)	84 (10%)	162 (17%)	122 (17%)	76 (19%)	

VARIABLE	eGFR (ml/min per 1.73 m2)					P
	<30	30-<40	40-<50	50-<60	>=60	
Tobacco use (n [%])						
Current Smoker	110 (16%)	123 (15%)	117 (12%)	84 (12%)	54 (14%)	0.01
	110 (16%)	123 (15%)	117 (12%)	84 (12%)	54 (14%)	0.05
>100 Cigarettes during lifetime	405 (61%)	500 (59%)	542 (56%)	375 (52%)	189 (48%)	0.0001
	405 (61%)	500 (59%)	542 (56%)	375 (52%)	189 (48%)	<0.001
Medical History (n [%])						
Hypertension	612 (92%)	767 (91%)	848 (88%)	587 (82%)	267 (67%)	0.0001
	612 (92%)	767 (91%)	848 (88%)	587 (82%)	267 (67%)	<0.001
Diabetes	352 (53%)	459 (54%)	448 (46%)	290 (40%)	130 (33%)	0.0001
	352 (53%)	459 (54%)	448 (46%)	290 (40%)	130 (33%)	<0.001
MI or coronary revascularization	170 (25%)	227 (27%)	227 (23%)	131 (18%)	51 (13%)	0.0001
	170 (25%)	227 (27%)	227 (23%)	131 (18%)	51 (13%)	<0.001
Chronic heart failure	97 (15%)	103 (12%)	91 (9%)	43 (6%)	19 (5%)	0.0001
	97 (15%)	103 (12%)	91 (9%)	43 (6%)	19 (5%)	<0.001
PAD	75 (11%)	85 (10%)	47 (5%)	31 (4%)	11 (3%)	0.0001
	75 (11%)	85 (10%)	47 (5%)	31 (4%)	11 (3%)	<0.001
BP variables						
SBP(mmHg; mean ±SD)	130.5 +/- 23.6	129.4 +/- 23.2	127.7 +/- 21.3	125.4 +/- 20.2	123.5 +/- 20.0	0.0001
	130.5 +/- 23.6	129.4 +/- 23.2	127.7 +/- 21.3	125.4 +/- 20.2	123.5 +/- 20.0	<0.0001
DBP (mmHg; mean ±SD)	69.9 +/- 13.3	70.1 +/- 12.6	71.5 +/- 12.7	72.3 +/- 12.3	74.9 +/- 12.8	0.0001
	69.9 +/- 13.3	70.1 +/- 12.6	71.5 +/- 12.7	72.3 +/- 12.3	74.9 +/- 12.8	<0.0001
MAP (mmHg; mean ±SD)	90.1 +/- 14.4	89.8 +/- 14.0	90.2 +/- 13.7	90.0 +/- 13.1	91.1 +/- 13.7	0.574
	90.1 +/- 14.4	89.8 +/- 14.0	90.2 +/- 13.7	90.0 +/- 13.1	91.1 +/- 13.7	0.682
BP>130/80 mmHg	335 (50%)	394 (47%)	466 (48%)	319 (45%)	164 (42%)	0.0004
	335 (50%)	394 (47%)	466 (48%)	319 (45%)	164 (42%)	0.037
Weight (kg; mean ±SD)	89.8 +/- 24.8	92.3 +/- 23.2	92.5 +/- 23.3	93.3 +/- 24.1	92.3 +/- 22.6	0.0311
	89.8 +/- 24.8	92.3 +/- 23.2	92.5 +/- 23.3	93.3 +/- 24.1	92.3 +/- 22.6	0.081

VARIABLE	eGFR (ml/min per 1.73 m2)					P
	<30	30-<40	40-<50	50-<60	>=60	
BMI (kg/m²; mean ±SD)	31.9 +/- 8.4	32.5 +/- 7.9	32.1 +/- 7.8	32.2 +/- 8.1	31.3 +/- 7.1	0.2129
	31.9 +/- 8.4	32.5 +/- 7.9	32.1 +/- 7.8	32.2 +/- 8.1	31.3 +/- 7.1	0.187
BMI (kg/m²; n [%])						0.9501
<25.0	132 (20%)	126 (15%)	149 (15%)	121 (17%)	73 (18%)	0.352
	132 (20%)	126 (15%)	149 (15%)	121 (17%)	73 (18%)	
25.0-29.9	182 (27%)	238 (28%)	275 (28%)	207 (29%)	112 (28%)	
	182 (27%)	238 (28%)	275 (28%)	207 (29%)	112 (28%)	
>=30.0	353 (53%)	480 (57%)	544 (56%)	392 (54%)	212 (53%)	
	353 (53%)	480 (57%)	544 (56%)	392 (54%)	212 (53%)	
ABI<0.9 (n [%])	155 (24%)	165 (20%)	143 (15%)	101 (14%)	18 (5%)	0.0001
	155 (24%)	165 (20%)	143 (15%)	101 (14%)	18 (5%)	<0.0001
Kidney function measures						
Adjusted serum creatinine □ (mg/dl; mean ±SD)	2.56 +/- 0.56	1.90 +/- 0.32	1.56 +/- 0.23	1.32 +/- 0.20	1.14 +/- 0.20	0.0001
	2.56 +/- 0.56	1.90 +/- 0.32	1.56 +/- 0.23	1.32 +/- 0.20	1.14 +/- 0.20	<0.0001
Urine Protein/24 h (g; median [IQR])	0.57 (0.14 to 2.14)	0.26 (0.08 to 1.22)	0.13 (0.07 to 0.60)	0.10 (0.06 to 0.36)	0.10 (0.06 to 0.22)	0.0001
	0.57 (0.14 to 2.14)	0.26 (0.08 to 1.22)	0.13 (0.07 to 0.60)	0.10 (0.06 to 0.36)	0.10 (0.06 to 0.22)	<0.0001

VARIABLE	eGFR (ml/min per 1.73 m2)					P
	<30	30-<40	40-<50	50-<60	>=60	
Lipoproteins (mg/dl; mean ±SD)						
Total cholesterol	183.3 +/- 51.6	182.5 +/- 46.3	183.3 +/- 42.1	183.2 +/- 41.2	183.5 +/- 39.2	0.7674
	183.3 +/- 51.6	182.5 +/- 46.3	183.3 +/- 42.1	183.2 +/- 41.2	183.5 +/- 39.2	>0.5
LDL cholesterol	99.9 +/- 38.6	100.4 +/- 35.6	103.3 +/- 34.8	104.5 +/- 33.2	107.2 +/- 32.6	0.0001
	99.9 +/- 38.6	100.4 +/- 35.6	103.3 +/- 34.8	104.5 +/- 33.2	107.2 +/- 32.6	0.0026
HDL cholesterol	46.7 +/- 15.5	47.4 +/- 15.7	48.2 +/- 14.8	48.8 +/- 16.0	50.2 +/- 16.4	0.0003
	46.7 +/- 15.5	47.4 +/- 15.7	48.2 +/- 14.8	48.8 +/- 16.0	50.2 +/- 16.4	0.0034
Triglycerides	167.8 +/- 126.8	162.3 +/- 123.0	150.8 +/- 99.0	148.3 +/- 127.4	128.6 +/- 81.5	0.0001
	167.8 +/- 126.8	162.3 +/- 123.0	150.8 +/- 99.0	148.3 +/- 127.4	128.6 +/- 81.5	<0.0001
Hemoglobin (g/dl; mean ±SD)	11.8 +/- 1.7	12.3 +/- 1.7	12.8 +/- 1.7	13.2 +/- 1.6	13.4 +/- 1.6	0.0001
	11.8 +/- 1.7	12.3 +/- 1.7	12.8 +/- 1.7	13.2 +/- 1.6	13.4 +/- 1.6	<0.0001
Serum calcium (mg/dl; mean ±SD)	9.1 +/- 0.6	9.2 +/- 0.5	9.2 +/- 0.5	9.2 +/- 0.5	9.2 +/- 0.4	0.0002
	9.1 +/- 0.6	9.2 +/- 0.5	9.2 +/- 0.5	9.2 +/- 0.5	9.2 +/- 0.4	<0.0001
Serum phosphate (mg/dl; mean ±SD)	4.1 +/- 0.8	3.8 +/- 0.6	3.6 +/- 0.6	3.5 +/- 0.6	3.4 +/- 0.5	0.0001
	4.1 +/- 0.8	3.8 +/- 0.6	3.6 +/- 0.6	3.5 +/- 0.6	3.4 +/- 0.5	
Total PTH (pg/ml; median [IQR])	104.5 (64.0 to 172.2)	63.9(41.0 to 100.2)	47.8(32.0 to 74.0)	40.9 (29.6 to 59.1)	36.0 (27.3 to 50.3)	0.0001
	104.5 (64.0 to 172.2)	63.9(41.0 to 100.2)	47.8(32.0 to 74.0)	40.9 (29.6 to 59.1)	36.0 (27.3 to 50.3)	
Blood glucose (mg/dl; median [IQR])	96.5 (85.0 to 124.0)	98.0 (87.0 to 131.0)	100.0 (88.0 to 127.0)	95.0 (85.0 to 119.0)	94.0 (84.0 to 110.0)	0.0003
	96.5 (85.0 to 124.0)	98.0 (87.0 to 131.0)	100.0 (88.0 to 127.0)	95.0 (85.0 to 119.0)	94.0 (84.0 to 110.0)	0.0002
Glycosylated hemoglobin (%; mean ±SD)	6.7 +/- 1.5	6.8 +/- 1.6	6.7 +/- 1.5	6.5 +/- 1.4	6.3 +/- 1.7	0.0001
	6.7 +/- 1.5	6.8 +/- 1.6	6.7 +/- 1.5	6.5 +/- 1.4	6.3 +/- 1.7	<0.0001
Serum uric acid (mg/dl; mean ±SD)	8.2 +/- 2.0	7.9 +/- 1.9	7.3 +/- 1.8	6.8 +/- 1.6	6.1 +/- 1.7	0.0001
	8.2 +/- 2.0	7.9 +/- 1.9	7.3 +/- 1.8	6.8 +/- 1.6	6.1 +/- 1.7	<0.0001

(a) Includes Asian/Pacific Islander and Native American individuals.

Appendix A

PUBLISHED ARTICLE

Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A, Robinson N, Teal V, Feldman HI; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. *Clin J Am Soc Nephrol.* 2009 Aug;4(8):1302-11.

Chronic Renal Insufficiency Cohort (CRIC) Study: Baseline Characteristics and Associations with Kidney Function

James P. Lash,* Alan S. Go,[†] Lawrence J. Appel,[‡] Jiang He,^{§||} Akinlolu Ojo,[¶] Mahboob Rahman,** Raymond R. Townsend,^{††} Dawei Xie,^{‡‡} Denise Cifelli,^{‡‡} Janet Cohan,* Jeffrey C. Fink,^{§§} Michael J. Fischer,^{*|||¶¶} Crystal Gadegbeku,[¶] L. Lee Hamm,[§] John W. Kusek,^{***} J. Richard Landis,^{‡‡} Andrew Narva,^{***} Nancy Robinson,^{‡‡} Valerie Teal,^{‡‡} and Harold I. Feldman,^{††‡‡} on behalf of the Chronic Renal Insufficiency Cohort (CRIC) Study Group

*Department of Medicine, University of Illinois at Chicago, Chicago Illinois; [†]Division of Research, Kaiser Permanente of Northern California, Oakland, California; [‡]Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland; Departments of [§]Medicine and ^{||}Epidemiology, Tulane University, New Orleans, Louisiana; [¶]Department of Medicine, University of Michigan, Ann Arbor, Michigan; **Department of Medicine, Case Western University, Cleveland, Ohio; ^{††}Department of Medicine and ^{‡‡}Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, Pennsylvania; ^{§§}Department of Medicine, University of Maryland, Baltimore, Maryland; ^{|||}Center for Management of Complex Chronic Care, Jesse Brown VAMC, Chicago, Illinois; ^{¶¶}Edward Hines VA, Maywood, Illinois; and ^{***}National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland

Background and objectives: The Chronic Renal Insufficiency Cohort (CRIC) Study was established to examine risk factors for the progression of chronic kidney disease (CKD) and cardiovascular disease (CVD) in patients with CKD. We examined baseline demographic and clinical characteristics.

Design, setting, participants, & measurements: Seven clinical centers recruited adults who were aged 21 to 74 yr and had CKD using age-based estimated GFR (eGFR) inclusion criteria. At baseline, blood and urine specimens were collected and information regarding health behaviors, diet, quality of life, and functional status was obtained. GFR was measured using radiolabeled iothalamate in one third of participants.

Results: A total of 3612 participants were enrolled with mean age \pm SD of 58.2 ± 11.0 yr; 46% were women, and 47% had diabetes. Overall, 45% were non-Hispanic white, 46% were non-Hispanic black, and 5% were Hispanic. Eighty-six percent reported hypertension, 22% coronary disease, and 10% heart failure. Mean body mass index was 32.1 ± 7.9 kg/m², and 47% had a BP >130/80 mmHg. Mean eGFR was 43.4 ± 13.5 ml/min per 1.73 m², and median (interquartile range) protein excretion was 0.17 g/24 h (0.07 to 0.81 g/24 h). Lower eGFR was associated with older age, lower socioeconomic and educational level, cigarette smoking, self-reported CVD, peripheral arterial disease, and elevated BP.

Conclusions: Lower level of eGFR was associated with a greater burden of CVD as well as lower socioeconomic and educational status. Long-term follow-up of participants will provide critical insights into the epidemiology of CKD and its relationship to adverse outcomes.

Clin J Am Soc Nephrol 4: 1302–1311, 2009. doi: 10.2215/CJN.00070109

The prevalence of ESRD that requires renal replacement therapy has risen dramatically in the United States during the past three decades (1). Non-dialysis-requiring chronic kidney disease (CKD) is substantially more common than ESRD, with an estimated 15 million adults in the

United States having CKD of stage 3 or worse (as defined by an estimated GFR [eGFR] of <60 ml/min per 1.73 m²) (2). Furthermore, CKD frequently progresses in severity, but the factors that are responsible for accelerated decline need further elucidation. In addition, recent studies have highlighted an important association between even mild CKD and increased risk for cardiovascular disease (CVD) (3), but the mechanisms for this association remain unclear.

In response to the epidemic of CKD and our incomplete understanding of factors that govern its progression and associated morbidity, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) established the Chronic Renal Insufficiency Cohort (CRIC) Study in 2001. The broad

Received January 5, 2009. Accepted May 7, 2009.

Published online ahead of print. Publication date available at www.cjasn.org.

This trial has been registered at www.clinicaltrials.gov (identifier NCT00304148).

Correspondence: Dr. James P. Lash, University of Illinois at Chicago, Department of Medicine/Section of Nephrology (MC 793), 820 South Wood Street, Chicago, IL 60612-7315. Phone: 312-996-7729; Fax: 312-996-7378; E-mail: jjplash@uic.edu

aims of the CRIC Study are to examine risk factors for the progression of kidney disease and CVD in patients with CKD and to develop predictive models to identify high-risk subgroups. The design and methods of the CRIC Study have been previously reported (4). In this article, we characterize the eligibility and recruitment methods, describe the baseline characteristics of patients enrolled in the cohort, and report initial analyses of correlates of level of eGFR.

Materials and Methods

Study Organization

The CRIC Study consists of a Scientific and Data Coordinating Center; seven clinical centers, central laboratories, and reading centers; a Scientific Advisory Committee; and NIDDK project scientists as described previously (4). The study protocol was approved by institutional review boards at participating institutions, and the research was conducted in accordance with the ethical principles of the Declaration of Helsinki.

Study Design

The CRIC Study was designed as a prospective cohort of approximately 3600 participants who were enrolled through seven clinical centers. A weighted random sample of approximately one third of the cohort (referred to as the subcohort) was assigned to undergo additional, more intensive testing (including iothalamate clearance studies to measure GFR and electron-beam tomography) that would also facilitate use of nested case-cohort substudies (4). CRIC participants are followed until death or withdrawal of informed consent. Follow-up continues even after ESRD occurs with initiation of chronic dialysis or receipt of a kidney transplant. Outcomes regarding progression of kidney dysfunction will focus principally on reductions in GFR as well as the occurrence of clinically relevant declines in renal function. Evaluation of subclinical CVD is assessed annually (*via* standard 12-lead electrocardiography and measurements of ankle-brachial index [ABI]), and transthoracic echocardiography is performed at years 1 and 4 of follow-up for all participants. Coronary artery calcium burden assessment using electron-beam tomography or multidetector computed tomography will be performed in the subcohort at years 1 and 4. Clinical cardiovascular outcomes (including acute myocardial infarction, heart failure, arrhythmias, stroke, and peripheral arterial disease [PAD]) will be ascertained every 6 mo during follow-up, and relevant medical records will be centrally adjudicated. Hypertension at entry was defined as either systolic BP ≥ 140 mmHg, diastolic BP ≥ 90 mmHg, or use of antihypertensive medications (5). Diabetes was defined as either fasting glucose ≥ 126 mg/dl, random glucose ≥ 200 mg/dl, or use of insulin or antidiabetic medication (6).

Study Population and Recruitment

Eligibility criteria. The CRIC Study was designed to include a racially and ethnically diverse group of adult patients who were aged 21 to 74 yr and had mild to moderate CKD and approximately half of whom had diabetes (Table 1). The age and eGFR criteria were specifically designed to facilitate evaluation of the progression and implications of CKD across a wide spectrum of mild to moderate kidney dysfunction and age. Age-based eGFR entry criteria were established to limit the proportion of older individuals who were recruited with age-related diminutions of GFR but otherwise nonprogressive CKD. The level of eGFR used to define eligibility was based on the four-variable Modification of Diet in Renal Disease (MDRD) estimating

equation (7), using locally measured serum creatinine calibrated to the Cleveland Clinic laboratory (8).

Exclusion criteria. Selected exclusion criteria were implemented (Table 2). Patients with polycystic kidney disease were excluded because of its distinct pathophysiology and its exclusive focus by another ongoing NIDDK-sponsored study (9). Patients with additional primary renal diseases were excluded when active immunosuppression had been used within 6 mo of enrollment. Patients with significant coexisting illnesses were also excluded, as detailed in Table 2.

Recruitment. The initial protocol called for each of the seven clinical centers to enroll approximately 450 participants each during a 33-mo period (May 2003 through March 2006). In August 2005, after Hurricane Katrina, enrollment at Tulane was halted after 405 participants had been enrolled. Consequently, the recruitment period was extended and recruitment targets at the other six clinical centers were increased. Study enrollment was completed on March 31, 2007. Recruitment strategies varied from center to center and included computerized searches of laboratory databases and hand searches of medical records and referrals from health care providers.

Screening, Enrollment, Follow-up, and Study Data Collection

A total of 5319 participants completed screening visits, at which time consent was obtained and eligibility was determined (Figure 1, Table 1). Of those screened, 4073 were found to be eligible and 3612 completed a baseline visit, defining membership in the cohort. Five individuals with an eGFR above the exclusion level completed the baseline visit in error and are included in our analyses. At the baseline visit, sociodemographic characteristics, medical history, lifestyle behaviors, and current medications were recorded. Standardized BP measurements were obtained using a previously validated protocol (10). Anthropometric measures (height, weight, and mid-abdominal waist circumference) were obtained, and body composition was assessed using bioelectrical impedance analysis techniques. ABI was measured using standard methods (11). A 12-lead electrocardiogram was obtained using standardized methods (12). GFR was assessed by the renal clearance of 125-iodine iothalamate (13) in the subcohort. As detailed in Table 1, a series of questionnaires were administered regarding quality of life, diet, cognitive function, depressive symptoms, and physical activity level. Plasma, urine, and nail samples were collected for initial study measures, and aliquots were also stored for future studies. Additional details regarding visit and contact schedule are provided in Table 1.

Statistical Analysis

The analytical plan for the CRIC Study has been previously described (4). Baseline characteristics are described using means with SD or medians and interquartile ranges for continuous variables, and frequency distribution is described with percentages for categorical variables. Missing values occurred when a participant failed to answer a question on a case report form or when a physical measure was not obtained or a laboratory test was not performed. The analysis for each variable is based on the observed values only. Baseline characteristics are compared between groups using *t* tests, ANOVA, or χ^2 tests, as appropriate. A two-sided $P \leq 0.05$ was considered statistically significant.

Results

Baseline Demographic and Clinical Characteristics of Participants

The final enrolled cohort has a mean \pm SD age of 58.2 ± 11.0 yr with excellent representation of women (46%) and patients

Table 1. Sequence and schedule of CRIC Study clinic visits/contacts and procedures^a

Parameter	Visit											
	Screening	Baseline	6 mo	12 mo	18 mo	24 mo	30 mo	36 mo	42 mo	48 mo	54 mo	60 mo
Type of contact	Visit	Visit	Phone	Visit	Phone	Visit	Phone	Visit	Phone	Visit	Phone	Visit
Informed consent	•											
Medical record consent				•		•		•		•		•
Contact information	•	•	•	•	•	•	•	•	•	•	•	•
Labs: creatinine, glucose	•											
Demographic information	•											
Eligibility confirmation	•											
Medical history		•		•		•		•		•		•
Genetic blood sample		•		•		•		•		•		•
Labs: CBC, metabolic panel, lipids		•		•		•		•		•		•
24-h urine		•		•		•		•		•		•
BP		•		•		•		•		•		•
Anthropometric measures		•		•		•		•		•		•
Ankle brachial index		•		•		•		•		•		•
Bioelectric impedance assessment		•		•		•		•		•		•
Nail clippings		•		•		•		•		•		•
Electrocardiogram		•		•		•		•		•		•
Echocardiogram				•						•		
EBT or MDCT (one third subcohort)				•						•		
Iothalamate-GFR (one third subcohort)		•				•				•		
Pulse wave velocity						•				•		
Physical assessment		•				•				•		
Medications		•	•	•		•		•		•		•
KDQOL quality of life (43)		•		•		•		•		•		•
Diet History Questionnaire (44)		•				•				•		
Mini Mental Status Exam (45)		•				•				•		
MDRD Symptom Index (46)		•		•		•		•		•		•
Beck Depression Inventory (47)		•				•				•		
Physical Activity (48,49)		•				•				•		
Kansas City Questionnaire (50)				•		•		•		•		•
Recent medical history		•	•	•	•	•	•	•	•	•	•	•

^aCBC, complete blood count; CRIC, Chronic Renal Insufficiency Cohort; EBT, electron-beam tomography; MDCT, multidetector computed tomography; MDRD, Modification of Diet in Renal Disease; KDQOL, Kidney Disease Quality of Life.

with diabetes (47%), consistent with the targeted enrollment goals (Table 3). The cohort is racially and ethnically diverse with 1638 (45%) non-Hispanic white patients, 1651 (46%) non-Hispanic black/African American patients, 169 (5%) Hispanic patients, and 154 (4%) Asian/Pacific Islander/Native American patients. Approximately 33% of the cohort had completed a college education, and 28% had annual incomes <\$20,000 (US). Nearly 90% of the cohort had a history of hypertension. Fewer than 25% of the cohort had a self-reported history of coronary disease or PAD. Although the mean systolic and diastolic BPs were approximately 128 mmHg and approximately 71 mmHg, respectively, 47% of participants had a baseline BP >130/80 mmHg at entry. Mean body mass index (BMI) was elevated at

32.1 ± 7.9 kg/m² with more than one half of all participants having a BMI >30 kg/m². Mean eGFR for the entire cohort was 43.4 ± 13.5 ml/min per 1.73 m², and median (IQR) proteinuria was 0.17 g per 24 h (0.07 to 0.81 g per 24 h). Almost 70% of the cohort was taking an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. Most participants had an eGFR consistent with National Kidney Foundation's stages 3 and 4 CKD (70 and 18%, respectively) (14).

Several differences also existed between participants with and without diabetes (Table 3). Compared with participants without diabetes, those with diabetes were more likely to be nonwhite and Hispanic and to earn annual incomes <\$20,000 but were less likely to have a college education (*P* = 0.0001).

Table 2. Eligibility and exclusion criteria


Eligibility criteria	
Age stratum (yr)/eligible eGFR range (ml/min per 1.73 m ²) ^a	
21 to 44/20 to 70	
45 to 64/20 to 60	
65 to 74/20 to 50	
Exclusion criteria	
institutionalized (e.g., prisoner, nursing home or skilled nursing facility resident)	
unable or unwilling to give consent	
unlikely or unable to participate in required study procedures	
New York Heart Association class III or IV heart failure (baseline)	
known cirrhosis	
known HIV infection and/or AIDS	
pregnant women	
previously received dialysis for {my}1 mo	
previous organ or bone marrow transplant	
received immunosuppressive or other immunotherapy for primary renal disease or systemic vasculitis within the past 6 mo	
previous chemotherapy or alkylating agents for systemic cancer other than non-melanoma skin cancer within 2 yr	
previous diagnosis of multiple myeloma or renal carcinoma	
polycystic kidney disease	
current participation in interventional clinical trial or in a research study	

^aBased on simplified Modification of Diet in Renal Disease (MDRD) equation.

Self-reported myocardial infarction/coronary revascularization, congestive heart failure, and PAD were nearly twice as common among participants with diabetes. Participants with diabetes were also more likely to have a history of hypertension, have mean baseline BP >130/80 mmHg, and have a BMI ≥30 (*P* = 0.0001). Furthermore, these participants had a two-fold greater prevalence of an ABI <0.9. Mean eGFR was lower and urine protein higher among participants with diabetes than among those without diabetes.

Baseline Characteristics by eGFR Level

As a result of enrollment strategies, there was relatively even distribution by race across eGFR strata (Table 4). In comparison with those who had higher eGFR, participants with lower eGFR tended to older, female, and Hispanic (*P* = 0.0001). Also, a trend existed between lower eGFR and a higher proportion of annual incomes <\$20,000, having only high school level education, BMI >30 kg/m², and history of >100 cigarettes. The prevalence of hypertension (and those with mean BP >130/80 mmHg), diabetes, CVD, PAD, and proteinuria were also significantly higher in lower eGFR groups (*P* = 0.0001). With



* Five participants with eGFR above the exclusion level were scheduled and completed the baseline visit in error.

Figure 1. Participant recruitment and follow-up flow diagram. *Five participants with estimated GFR above the exclusion level were scheduled and completed the baseline visit in error.

lower eGFR, there were progressive decreases in mean hemoglobin and increases in mean serum phosphorus and total parathyroid hormone (*P* = 0.0001).

Select Anticipated and Actual Recruitment Targets

Recruitment by racial and ethnic groups was similar to anticipated target goals (Table 5). In contrast, the actual recruitment of young participants with (3.99%) and without diabetes (9.51%) was less than the targeted goal of 12.5% for both subgroups (Table 6).

Discussion

The CRIC Study was designed to examine risk factors for CKD progression and CVD incidence and progression among a large, representative cohort of individuals with CKD. The CRIC cohort enrolled a diverse set of participants who had CKD and possessed a broad range of kidney dysfunction and other potentially important prognostic attributes. Recruitment goals regarding race/ethnicity, gender, age, and diabetes status were largely met. The strength of the CRIC Study lies in the diverse characteristics of the assembled cohort and the comprehensive data collection activities that have been designed to address gaps in our understanding of CKD-associated morbidity and mortality and to identify potential targets for trials of preventive therapies.

The baseline findings regarding diabetic status and level of kidney function support that the assembled cohort has characteristics representative of the broader CKD population. As expected, participants with diabetes in the cohort were more likely to have self-reported CVD than those without diabetes.

Table 3. Baseline demographic and clinical characteristics of participants^a

Variable	Cohort (n = 3612)	Subcohort with iGFR (n = 1288)	Diabetes (n = 1683)	No Diabetes (n = 1929)	P for Diabetes versus No Diabetes
Age (yr; mean ± SD)	58.2 ± 11.0	56.1 ± 12.5	59.5 ± 9.8	57.1 ± 11.8	0.0001
Gender (n [%])					0.2516
male	1959 (54)	713 (55)	931 (55)	1028 (53)	
female	1653 (46)	575 (45)	754 (45)	899 (47)	
Racial/ethnic group (n [%])					0.0001
non-Hispanic white	1638 (45)	713 (46)	931 (39)	1028 (51)	0.2516
non-Hispanic black/ African American	1651 (46)	532 (41)	849 (50)	802 (42)	
Hispanic	169 (5)	69 (5)	111 (7)	58 (3)	
other ^b	154 (4)	99 (8)	76 (5)	78 (4)	0.0001
Annual household income (n [%])					0.0001
≤\$20,000	1009 (28)	297 (23)	565 (34)	444 (23)	
\$20,001 to \$50,000	906 (25)	338 (26)	432 (26)	474 (24)	
\$50,001 to \$100,000	725 (20)	306 (24)	281 (17)	444 (23)	
>\$100,000	389 (11)	153 (12)	134 (8)	255 (13)	
no response	583 (16)	193 (15)	271 (16)	312 (16)	
Educational attainment (n [%])					0.0001
<7th grade	60 (2)	16 (1)	41 (2)	19 (1)	
7th to 12th grade	545 (15)	153 (12)	319 (19)	226 (12)	
high school diploma	695 (19)	239 (19)	339 (20)	356 (18)	
vocational degree	184 (5)	64 (5)	98 (6)	86 (4)	
some college	921 (26)	319 (25)	440 (26)	481 (25)	
college graduate	696 (19)	298 (23)	281 (17)	415 (22)	
graduate degree	510 (14)	198 (15)	167 (10)	343 (18)	
Tobacco use (n [%])					
current smoker	494 (14)	151 (12)	212 (13)	282 (15)	0.0733
>100 cigarettes during lifetime	2019 (56)	667 (52)	983 (58)	1036 (54)	0.0057
Medical history (n [%])					
hypertension	3094 (86)	1091 (85)	1552 (92)	1542 (80)	0.0001
MI or coronary revascularization	810 (22)	225 (17)	493 (29)	317 (17)	0.0001
chronic heart failure	357 (10)	86 (7)	245 (15)	112 (6)	0.0001
PAD	250 (7)	80 (6)	181 (11)	69 (4)	0.0001
BP variables					
SBP (mmHg; mean ± SD)	127.7 ± 21.9	127.8 ± 21.3	132.4 ± 22.5	123.6 ± 20.5	0.0001
DBP (mmHg; mean ± SD)	71.4 ± 12.8	72.4 ± 12.7	69.4 ± 12.9	73.1 ± 12.8	0.0001
MAP (mmHg; mean ± SD)	90.2 ± 13.8	90.9 ± 13.2	90.4 ± 13.9	89.9 ± 13.6	0.3113
BP >130/80 mmHg (n [%])	1686 (47)	626 (49)	882 (53)	804 (42)	0.0001
Weight (kg; mean ± SD)	92.0 ± 23.7	89.9 ± 21.2	97.7 ± 24.2	87.1 ± 22.1	0.0001
BMI (kg/m ² ; mean ± SD)	32.1 ± 7.9	31.3 ± 7.0	34.1 ± 8.2	30.3 ± 7.2	0.0001
BMI (kg/m ² ; n [%])					0.0001
<25.0	607 (17)	234 (18)	179 (11)	428 (22)	
25.0 to 29.9	1017 (28)	380 (30)	388 (23)	629 (33)	0.0001
>30.0	1987 (55)	673 (52)	1118 (67)	869 (45)	
ABI<0.9 (n [%])	526 (15)	173 (14)	335 (20)	191 (10)	0.0001
Kidney function measures					
adjusted serum creatinine (mg/dl; mean ± SD)	1.73 ± 0.57	1.68 ± 0.56	1.80 ± 0.56	1.66 ± 0.56	0.0001
eGFR (ml/min/1.73 m ² ; mean ± SD)	43.4 ± 13.5	45.2 ± 14.1	41.4 ± 12.9	45.1 ± 13.8	0.0001
eGFR (ml/min/1.73 m ² ; n [%])					0.0001
<15	3 (0)	2 (0)	1 (0)	2 (0)	
15 to 29	664 (18)	206 (16)	351 (21)	313 (16)	
30 to 59	2532 (70)	887 (69)	1197 (71)	1335 (70)	
60 to 89	389 (11)	187 (15)	126 (8)	263 (14)	
>90	8 (0)	4 (0)	4 (0)	4 (0)	
urine protein/24 h (g; median [IQR])	0.17 (0.07 to 0.81)	0.18 (0.07 to 0.90)	0.32 (0.09 to 1.49)	0.11 (0.06 to 0.43)	0.0001
ACEI or ARB therapy (n [%])	2462 (68)	880 (68)	1336 (79)	1126 (58)	0.0001
Lipoproteins (mg/dl; mean ± SD)					
total cholesterol	183.0 ± 44.5	183.8 ± 47.1	177.0 ± 47.2	188.2 ± 41.3	0.0001
LDL cholesterol	102.5 ± 35.0	103.4 ± 36.6	96.4 ± 36.4	107.8 ± 33.7	0.0001
HDL cholesterol	48.1 ± 15.6	47.5 ± 15.7	45.7 ± 13.9	50.2 ± 16.8	0.0001
triglycerides	154.2 ± 115.6	152.2 ± 112.5	166.2 ± 130.3	143.6 ± 99.8	0.0001
Hemoglobin (g/dl; mean ± SD)	12.7 ± 1.8	12.6 ± 1.7	12.1 ± 1.7	13.2 ± 1.7	0.0001
Serum calcium (mg/dl; mean ± SD)	9.2 ± 0.5	9.2 ± 0.5	9.1 ± 0.5	9.2 ± 0.5	0.0001
Serum phosphorus (mg/dl; mean ± SD)	3.7 ± 0.7	3.7 ± 0.7	3.9 ± 0.7	3.6 ± 0.6	0.0001
Total PTH (pg/ml; median [IQR])	53.0 (34.0 to 88.0)	52.9 (34.0 to 85.0)	60.0 (37.1 to 102.4)	48.5 (32.5 to 78.0)	0.0001
Blood glucose (mg/dl; median [IQR])	97.0 (86.0 to 124.0)	97.0 (86.0 to 121.0)	127.0 (100.0 to 163.0)	90.0 (84.0 to 98.0)	0.0001
Glycosylated hemoglobin (%; mean ± SD)	6.6 ± 1.6	6.6 ± 1.6	7.7 ± 1.7	5.7 ± 0.5	0.0001

^aABI, ankle-brachial index; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; DBP, diastolic BP; eGFR, estimated GFR; iPTH, intact parathyroid hormone; IQR, interquartile range; MAP, mean arterial pressure; MI, myocardial infarction; PAD, peripheral arterial disease; SBP, systolic BP.

^bIncludes Asian/Pacific Islander and Native American individuals.

Table 4. Baseline characteristics by eGFR level

Variable	eGFR (ml/min per 1.73 m ²)					P
	<30	30 to <40	40 to <50	50 to <60	≥60	
<i>n</i>	667	844	968	720	397	
Age (yr; mean ± SD)	58.7 ± 11.2	59.6 ± 11.0	60.0 ± 10.4	57.7 ± 10.1	51.5 ± 11.0	0.0001
Gender (<i>n</i> [%])						0.0001
male	311 (47)	440 (52)	568 (59)	406 (56)	226 (57)	
female	356 (53)	404 (48)	400 (41)	314 (44)	171 (43)	
Racial/ethnic group (<i>n</i> [%])						0.0673
non-Hispanic white	277 (42)	386 (46)	461 (48)	348 (48)	160 (40)	
non-Hispanic black/African American	303 (45)	387 (46)	430 (44)	319 (44)	202 (51)	
Hispanic	55 (8)	43 (5)	32 (3)	21 (3)	18 (5)	
other ^a	32 (5)	28 (3)	45 (5)	32 (4)	17 (4)	0.0001
Annual household income (<i>n</i> [%])						0.1435
≤\$20,000	249 (37)	292 (35)	232 (24)	155 (22)	72 (18)	
\$20,001 to \$50,000	179 (27)	199 (24)	267 (28)	162 (23)	96 (24)	
\$50,001 to \$100,000	103 (17)	150 (18)	187 (19)	171 (24)	108 (27)	
>\$100,000	38 (6)	69 (8)	117 (12)	115 (16)	49 (12)	
no response	93 (14)	134 (16)	165 (17)	117 (16)	72 (18)	
Educational attainment (<i>n</i> [%])						0.0001
<7th grade	27 (4)	15 (2)	10 (1)	4 (1)	2 (1)	
7th to 12th grade	126 (18)	160 (19)	143 (15)	82 (11)	27 (7)	
high school diploma	145 (22)	177 (21)	189 (20)	112 (16)	69 (17)	
vocational degree	36 (5)	38 (5)	48 (5)	36 (5)	26 (7)	
some college	162 (24)	224 (27)	228 (24)	192 (27)	112 (28)	
college graduate	106 (16)	146 (17)	188 (19)	172 (24)	82 (21)	
graduate degree	65 (10)	84 (10)	162 (17)	122 (17)	76 (19)	
Tobacco use (<i>n</i> [%])						0.0001
current smoker	110 (16)	122 (15)	117 (12)	84 (12)	54 (14)	0.0001
>100 cigarettes during lifetime	405 (61)	500 (59)	542 (56)	375 (52)	139 (48)	0.0189
Medical history (<i>n</i> [%])						0.0001
hypertension	612 (92)	767 (91)	848 (88)	587 (82)	267 (67)	0.0001
diabetes	352 (53)	459 (54)	448 (46)	290 (40)	130 (33)	0.0001
MI or coronary revascularization	170 (26)	227 (27)	227 (23)	131 (18)	51 (13)	0.0001
chronic heart failure	97 (15)	103 (12)	91 (10)	43 (6)	19 (5)	0.0001
PAD	75 (11)	85 (10)	47 (5)	31 (4)	11 (4)	0.0001
BP variables						
SBP (mmHg; mean ± SD)	130.5 ± 23.6	129.4 ± 23.2	127.7 ± 21.3	125.4 ± 20.2	123.5 ± 20.0	0.0001
DBP (mmHg; mean ± SD)	69.9 ± 13.3	70.0 ± 12.6	71.5 ± 12.7	72.3 ± 12.3	74.9 ± 12.8	0.0001
MAP (mmHg; mean ± SD)	90.1 ± 14.4	89.8 ± 14.0	90.2 ± 13.7	90.0 ± 13.1	91.1 ± 13.6	0.6042
BP >130/80 (mmHg; <i>n</i> [%])	335 (50)	394 (47)	466 (48)	319 (45)	164 (42)	0.0001
Weight (kg; mean ± SD)	89.8 ± 24.8	92.3 ± 23.2	92.5 ± 23.3	93.3 ± 24.1	92.4 ± 22.6	0.0311
BMI (kg/m ² ; mean ± SD)	31.9 ± 8.4	32.5 ± 7.9	32.1 ± 7.8	32.2 ± 8.1	31.3 ± 7.1	0.2313
BMI category (kg/m ² ; <i>n</i> [%])						0.9367
<25.0	134 (20)	128 (15)	150 (15)	121 (17)	74 (19)	
25.0 to 29.9	182 (27)	238 (28)	275 (28)	206 (29)	112 (28)	0.0001
>30	353 (53)	480 (57)	544 (56)	392 (55)	212 (54)	
ABI <0.9	142 (22)	149 (18)	125 (13)	93 (13)	15 (4)	0.0001
Roche adjusted creatinine (mean ± SD)	2.56 ± 0.56	1.90 ± 0.32	1.56 ± 0.23	1.32 ± 0.20	1.14 ± 0.20	0.0001
Urine protein/24 h (g; median [IQR])	0.58 (0.15 to 2.14)	0.26 (0.08 to 1.22)	0.13 (0.07 to 0.60)	0.10 (0.06 to 0.36)	0.10 (0.06 to 0.22)	0.0001
Lipoproteins						
total cholesterol (mg/dl; mean ± SD)	183.3 ± 51.2	182.5 ± 46.2	183.1 ± 42.1	183.2 ± 41.3	183.5 ± 39.6	0.8297
LDL cholesterol (mg/dl; mean ± SD)	99.7 ± 37.9	100.2 ± 35.3	103.1 ± 34.6	104.4 ± 33.3	107.3 ± 32.6	0.0001
HDL cholesterol (mg/dl; mean ± SD)	46.9 ± 15.5	47.4 ± 15.8	48.2 ± 14.9	48.8 ± 16.0	50.2 ± 16.4	0.0004
triglycerides (mg/dl; mean ± SD)	168.1 ± 127.2	163.0 ± 123.4	151.4 ± 99.6	148.5 ± 127.2	129.9 ± 81.6	0.0001
Hemoglobin (g/dl; mean ± SD)	11.8 ± 1.7	12.3 ± 1.7	12.8 ± 1.7	13.2 ± 1.6	13.4 ± 1.6	0.0001
Serum calcium (mg/dl; mean ± SD)	9.1 ± 0.6	9.2 ± 0.5	9.2 ± 0.5	9.2 ± 0.5	9.2 ± 0.4	0.0002
Total iPTH (pg/ml; median [IQR])	105.0 (64.0 to 172.0)	63.9 (41.0 to 100.0)	47.5 (32.0 to 74.0)	41.0 (29.7 to 59.1)	36.0 (27.3 to 50.3)	0.0001
Serum phosphorus (mg/dl; mean ± SD)	4.1 ± 0.8	3.8 ± 0.6	3.6 ± 0.6	3.5 ± 0.6	3.4 ± 0.5	0.0001
Blood glucose (mg/dl; median [IQR])	97.0 (85.0 to 124.0)	98.0 (87.0 to 131.0)	100.0 (88.0 to 127.0)	95.0 (85.0 to 119.0)	94.0 (84.0 to 110.0)	0.0003
Glycosylated hemoglobin (%; mean ± SD)	6.7 ± 1.5	6.8 ± 1.6	6.7 ± 1.5	6.5 ± 1.4	6.3 ± 1.7	0.0001
Serum uric acid (mg/dl; mean ± SD)	8.2 ± 2.0	7.9 ± 1.9	7.3 ± 1.8	6.8 ± 1.6	6.2 ± 1.7	0.0001

^aIncludes Asian/Pacific Islander and Native American individuals.

Table 5. Select anticipated and actual recruitment targets: Race/ethnic target distribution in CRIC Study

Race/Ethnic Group	Anticipated (%)	Actual (%)
Non-Hispanic white	47.50	45.34
Non-Hispanic black	47.50	45.92
Other ^a	5.00	8.75

^aFor the purposes of recruitment goal, other group includes Hispanic, Asian/Pacific Islander, and Native American individuals.

Table 6. Select anticipated and actual recruitment targets: Age- and diabetes-status distribution in CRIC Study

Age Stratum (yr)	Anticipated Recruitment (%)		Actual Recruitment Cohort (%)	
	No Diabetes	Diabetes	No Diabetes	Diabetes
21 to 44	12.50	12.50	9.51	3.99
45 to 64	25.00	25.00	29.72	27.75
65 to 74	12.50	12.50	14.56	14.47

The findings in the CRIC subgroup with diabetes reinforce the findings from clinical trials that indicate that the CVD burden in the ESRD population with diabetes has its beginnings earlier during the course of CKD (15,16). In addition, lower levels of eGFR were associated with a greater burden of CVD. This is consistent with the increasing evidence for the presence and severity of CKD as an independent and graded risk factor for CVD events (3). By using sophisticated measurements of kidney function and subclinical CVD, the CRIC Study will provide insights into the pathophysiology of this relationship and will enable an assessment of both traditional and nontraditional risk factors.

Noteworthy is the high prevalence of several potentially modifiable risk factors in this CKD cohort. Almost half of all participants had a BP level above the recommended goal (17). Suboptimal levels of BP control have been reported in other CKD cohorts (18,19), and the findings in the CRIC cohort reinforce the need to raise awareness of effective BP management in CKD as a public health priority. As well, we observed a high prevalence of obesity among participants with and without diabetes. It has been suggested that higher BMI may be an independent risk factor for CKD (20–22) and progression to ESRD that requires dialysis (23). The modest association between lower eGFR and previous cigarette exposure is consistent with the previously described association of smoking with CKD (24). This relationship is also of particular interest because it may represent another potential risk factor. Longitudinal follow-up of CRIC participants will afford a more rigorous assessment of these newly recognized but less studied risk factors on CVD and CKD outcomes.

We also observed an important association between lower eGFR and both lower socioeconomic status (SES) and lesser educational attainment. It is known that lower SES is associated with ESRD (25,26). Analyses of several cohorts found an association between lower SES and progressive CKD (27–29). The CRIC Study will facilitate evaluation of the impact of SES and educational level in individuals with more advanced stages of CKD and potential mediating pathways that could have important health policy implications.

Previous epidemiologic studies of the relationship between CKD and CVD have come from various sources, including *post hoc* analyses of clinical trials (30–33), large cohort studies focused on non-CKD populations (34–37), and analyses of large datasets from major health care providers (3,38). Despite the important contributions made by these studies, major gaps in our knowledge remain. The CRIC Study will occupy a unique niche because of its use of observational epidemiology in a large cohort of patients with CKD and its use of longitudinal state-of-the-art measurements of kidney function and subclinical CVD. In addition to examining risk factors for CKD and CVD progression, the CRIC Study will facilitate the development of predictive models that identify high-risk groups; the determination of exposure–outcome relationships; and the evaluation of the impact of CKD and progressive CKD on quality of life, functional status, and resource use. Unlike most previous studies, the CRIC Study continues to follow participants after progression to ESRD, thereby providing an important opportunity to study the critical period when patients transition from CKD to ESRD.

Concurrent with the CRIC Study, several ongoing studies are examining risk factors for CKD. The National Health and Nutrition Examination Survey (NHANES) monitors CKD prevalence and risk factors over time (2,39). The National Kidney Foundation's Kidney Evaluation Education Program (KEEP) collects data characterizing CKD in the community among at-risk subgroups (40). The African American Study of Kidney Disease and Hypertension (AASK) (41) is investigating factors that influence CKD progression among black individuals with hypertensive kidney disease. Internationally, the CKD-Japan Cohort Study (CKD-JAC) is in the early stages of follow-up. The information gained from the CRIC Study will be complementary to and extend the important work accomplished by these studies. As an example, compared with the population-based NHANES CKD cohort (2), the CRIC cohort is older and by design has more advanced CKD with more even distribution across eGFR strata, a larger percentage of individuals with diabetes, and a larger representation of black participants to facilitate more robust subgroup analyses.

As with all prospective observational studies, inferences regarding causality will be limited by potential biases and residual confounding. Numerous methodologic strategies have been adopted to minimize these limitations and enhance the robustness of etiologic inferences drawn from this study. Another potential limitation is underrepresentation of young individuals with diabetes. To adapt to this, this group was oversampled for recruitment into the subcohort from which more detailed assessments of kidney function and cardiovascular health will

be obtained. In addition, the less-than-anticipated recruitment of Hispanic individuals will be addressed by the ongoing supplemental recruitment of >330 Hispanic participants at the University of Illinois at Chicago.

The observed low level of proteinuria could also have potential implications for future risk of cardiovascular and renal events; however, the high prevalence of self-reported comorbidities suggests that the cohort is at increased risk for adverse events. Furthermore, in the AASK, there was significant progression of CKD despite relatively low levels of baseline proteinuria (42). It is also important to note that findings from the CRIC Study may not be generalizable to certain types of kidney disease that was poorly represented in the cohort, such as glomerulonephritis. It was not intended for the study to be representative of all patients with CKD; rather, it was designed to be broadly representative of the ESRD population in which diabetes and hypertension are reported as the primary diagnoses for >70% of patients (1). Finally, analyses included self-reported comorbidities, which are subject to inherent limitations with regard to accuracy.

The CRIC Study has assembled a large and diverse CKD cohort with characteristics that are generalizable to CKD populations managed in different practice settings in the United States. Analogous to the Framingham Heart and Atherosclerosis Risk in Communities Studies, the CRIC Study will use observational epidemiology to answer key questions about the cause, prognosis, management, clinical outcomes, health service use, and quality of life in CKD. The knowledge generated from the CRIC Study will lead to the formulation of hypotheses regarding potentially modifiable pathways that will serve as the basis for targeted interventional trials that focus on reducing the burden of CKD and CVD.

Acknowledgments

In addition to funding under a cooperative agreement from National Institute of Diabetes and Digestive and Kidney Diseases (5U01DK060990, 5U01DK060984, 5U01DK06102, 5U01DK061021, 5U01DK061028, 5U01DK060980, 5U01DK060963, and 5U01DK060902), this work was supported in part by the following institutional Clinical Translational Science Awards and other National Institutes of Health grants: Johns Hopkins University UL1 RR-025005, University of Maryland GRCR M01 RR-16500, Case Western Reserve University Clinical and Translational Science Collaborative (University Hospitals of Cleveland, Cleveland Clinic Foundation, and MetroHealth) UL1 RR-024989, University of Michigan GCRC M01 RR-000042 and CTSA UL1 RR-024986, University of Illinois at Chicago Clinical Research Center, M01 RR-013987-06, Tulane/LSU/Charity Hospital General Clinical Research Center RR-05096, and Kaiser NIH/NCRR UCSF-CTSI UL1 RR-024131 and 5K24DK002651. Additional support provided by the National Center for Minority Health and Health Disparities, National Institutes of Health, and Department of Veterans Affairs (Career Development Award to M.J.F.).

University of Pennsylvania, Scientific & Data Coordinating Center: Harold I. Feldman, MD, MSCE (principal investigator), J. Richard Landis, PhD, Shawn Ballard, MS, Zhen Chen, PhD, Denise Cifelli, Robert M. Curley, MS, James Dattilo, Marie Durborow, Stephen Durborow, Susan Eachus, PhD, Melanie Glenn, MPH, Asaf Hanish, MPH, Christopher Helker, MSPH, Maximilian Herlim, Amanda Hyre, PhD, MPH, Marshall Joffe, MD, PhD, MPH, Hopiy Kim, Stephen E. Kimmel, MD,

Shiriki Kumanyika, PhD, MPH, Lisa Nessel, MSS, MLSP, Emile R. Mohler, III, MD, Gargi Parikh, MS, Amy Praestgard, MS, Nancy Robinson, MS, Leigh Rosen, MUEP, J. Sanford Schwartz, MD, Sandra Smith, Joan Stahl, MS, Valerie L. Teal, MS, Dawei Xie, PhD, Peter Yang, PhD; **University of Pennsylvania Medical Center:** Raymond R. Townsend, MD (principal investigator), Thomas Capolla, MD, ScM (ancillary investigator), Debbie Cohen, MD, Magdalena Cuevas, Mark J. Duckworth, Virginia Ford, MSN, CRNP, Colin M. Gorman, Juan Grunwald, MD (ancillary investigator), Lucy Kibe, MS, Mary B. Leonard, MD, MSCE (ancillary investigator), Maureen Maguire, PhD (ancillary investigator), Stephanie McDowell, John Murphy, MD, Muredach Reilly, MB (ancillary investigator), Sylvia E. Rosas, MD (ancillary investigator), Wanda M. Seamon, Angie Sheridan, MPH, Karen Teff, MD; **The Johns Hopkins University:** Lawrence J. Appel, MD, MPH (principal investigator), Cheryl Anderson, PhD, MPH, Brad Astor, PhD, MPH, Jeanne Charleston, RN, Bernard Jaar, MD, MPH, Edgar “Pete” Miller, MD, Patience Ngoh, Hemalatha Venkatesh, J. Hunter Young, MD, MHS; **University of Maryland:** Jeffrey Fink, MD, MS (co-principal investigator), Wanda Fink, RN, BSN, Afshin Parsa, MD, MPH, Beth Scism, Stephen Seliger, MD, MS, Matthew Weir, MD; **University Hospitals of Cleveland Case Medical Center:** Mahboob Rahman, MD (principal investigator), Renita Brooks, Valori Corrigan, RN, Genya Kisin, MA, Radhika Kanthety, Louise Strauss, RN, Jackson T. Wright, Jr., MD, PhD; **MetroHealth Medical Center:** Patricia Kao (co-principal investigator), Kim Bauchens, RN, Jacqui Bjaloncik, Jeffrey Schelling, MD, John R. Sedor, MD, Mary Ann Shella, RN, BSN, Jacqueline Theurer, J. Daryl Thornton, MD, MPH; **Cleveland Clinical Foundation:** Martin J. Schreiber, MD (co-principal investigator), Martha Coleman, RN, Richard Fatica, MD, David Frey, Darla Greenwald, Sandra Halliburton, PhD, Carol Horner, BSN, RN, Teresa Markle, BS, Sandra Pangonis, RN, Carmen Parades, MD, Mohammed A. Rafey, MD, MS, Annette Russo, Stephanie Slattery, RN, Jackie Soos, Rita Spirko, RN, MSN, Kay Stelmach, RN, Velma Stephens, LPN; **University of Michigan at Ann Arbor:** Akinlolu Ojo, MD, PhD (principal investigator), Anil Attili, MD, Jeff Briesmiester, Tonya L. Corbin, MD, Denise Cornish-Zirker, BSN, Crystal Gadegbeku, MD, Nancy Hill, Kenneth Jamerson, MD, Bruce Robinson, MD, Rajiv Saran, MD, Bonnie Welliver, BSN, CNN, Jillian Wilson, Eric Young, MD, MS; **St. John’s Health System:** Susan P. Steigerwalt, MD, FACP (co-principal investigator), Keith Bellovich, DO, Jennifer DeLuca, Sherry Gasko, BSRN, Gail Makos, RN, MSN, Chantal Parmelee, Shahan Smith, Kathleen Walls; **Wayne State University:** John M. Flack, MD, MPH (co-principal investigator), Andrew Johnson III, RN, Mary Maysura, Barbara Lloyd, MA, RD, Stephen Migdal, MD, M. Jena Mohanty, MD, Yanni Zhuang, BSN; **University of Illinois at Chicago:** James P. Lash, MD (principal investigator), Jose Arruda, MD, Carolyn Brecklin, MD, Janet Cohan, MSN, Michael Fischer, MD, MSPH, Leon Fogelfeld, Anne Frydrych, MS, RD, Claudia Lora (ancillary investigator), MD, Onesema Martinez, Patricia Meslar, MSN, Kalyani Perumal, MD, Thomas Stamos, MD, Gregg Vachon, Paul Vaitkus, MD, Eve Van Cauter (ancillary investigator), PhD, Julio C. Vijil, MD (ancillary investigator); **Tulane University Health Science Center:** Jiang He, MD, PhD (principal investigator), Brent Alper, MD, Vecihi Batuman, MD, Lydia A. Bazzano, MD, PhD, Bernadette Borja, Adriana Burridge, Jing Chen, MD, MSc, Catherine Cooke, Patrice Delafontaine, MD, Karen B. DeSalvo, MD, MPH, MSc, Vivian A. Fonseca, MD, Lee Hamm, MD, Michelle R. Hurly, RN, BSN, Eva Lustigova, MPH, Paul Muntner, PhD (ancillary investigator), Lindsey Powers, Paul Whelton, MD, MSc; **Kaiser Permanente of Northern California:** Alan S. Go, MD (principal investigator), Lynn M. Ackerson, PhD, Pete Dorin, MPA, Daniel Fernandez, Rosy Fox, Nancy G. Jensvold, MPH, Joan C. Lo, MD, Juan D. Ordonez, MD, MPH, Rachel Perloff, Thida Tan, MPH, Daphne Thompson, Gina M. Valladares, Annette Wiggins, RN, Diana B. Wong, RN,

MPH, Jingrong (Michelle) Yang, MA; *University of California, San Francisco*: Chi-yuan Hsu, MD, MSc (co-principal investigator), Glenn M. Chertow, MD, MPH, Nisha Bansal, MD, Irina Gorodetskaya, Vanessa Grubbs, MD (ancillary investigator), Manju Kurella, MD, MPH (ancillary investigator), Lowell Lo, MD, Michael G. Shlipak, MD, MPH (ancillary investigator), Kristine Yaffe, MD (ancillary investigator); *NIDDK*: John W. Kusek, PhD, Andrew S. Narva, MD; *Scientific Advisory Committee*: Kathy Faber-Langendoen, MD, Bryce A. Kiberd, MD, Elisa T. Lee, PhD, Julia Lewis, MD, William McClellan, MD, MPH, Timothy Meyer, MD, David Nathan, MD, John B. Stokes, MD, Herman Taylor, MD, Peter W. Wilson, MD; *University of New Mexico*: Dominic Raj, MD, DM (ancillary investigator), Vallabh Shah, PhD (ancillary investigator); *Consultants- Harvard School of Med*: Paul M. Ridker, MD; *Central Lab-University of Pennsylvania*: Daniel J. Rader, MD, Anna DiFlorio, Ted Mifflin, Linda Morrell, Megan L. Wolfe; *GFR Lab-Cleveland Clinic*: Phillip Hall, MD, Sue Saunders; *EBT Reading Center- UCLA*: Mathew Budoff, MD, Chris Dailing; *ECG Reading Center- Wake Forest*: Ronald Prineas, MD, PhD, Elsayed Soliman, MD, Zhu-Ming Zhang, MD; *Echo Reading Center-University of Pennsylvania*: Martin St. John Sutton, MBBS, Martin G. Keane, MD, FACC, FAHA

We thank the CRIC participants for time and commitment to the study.

Disclosures

None.

References

1. US Renal Data System: Excerpts from the United States Renal Data System 2006 Annual Data Report. *Am J Kidney Dis* 49: A6–A296, 2007
2. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. *JAMA* 298: 2038–2047, 2007
3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med* 351: 1296–1305, 2004
4. Feldman HI, Appel LJ, Chertow GM, Cifelli D, Cizman B, Daugirdas J, Fink JC, Franklin-Becker ED, Go AS, Hamm LL, He J, Hostetter T, Hsu CY, Jamerson K, Joffe M, Kusek JW, Landis JR, Lash JP, Miller ER, Mohler ER III, Muntner P, Ojo AO, Rahman M, Townsend RR, Wright JT: The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and methods. *J Am Soc Nephrol* 14[Suppl]: S148–S153, 2003
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. *JAMA* 289: 2560–2572, 2003
6. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 29[Suppl 1]: S43–S48, 2006
7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 130: 461–470, 1999
8. Coresh J, Astor BC, McQuillan G, Kusek J, Greene T, Van Lente F, Levey AS: Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. *Am J Kidney Dis* 39: 920–929, 2002
9. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, Wetzel LH, Baumgarten DA, Kenney PJ, Harris PC, Klahr S, Bennett WM, Hirschman GN, Meyers CM, Zhang X, Zhu F, Miller JP: Volume progression in polycystic kidney disease. *N Engl J Med* 354: 2122–2130, 2006
10. Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, Morgenstern BZ: Human blood pressure determination by sphygmomanometry. *Circulation* 88: 2460–2470, 1993
11. McDermott MM, Criqui MH, Liu K, Guralnik JM, Greenland P, Martin GJ, Pearce W: Lower ankle/brachial index, as calculated by averaging the dorsalis pedis and posterior tibial arterial pressures, and association with leg functioning in peripheral arterial disease. *J Vasc Surg* 32: 1164–1171, 2000
12. Vitelli LL, Crow RS, Shahar E, Hutchinson RG, Rautaharju PM, Folsom AR: Electrocardiographic findings in a healthy biracial population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. *Am J Cardiol* 81: 453–459, 1998
13. Hall PM, Rolin H: Iothalamate clearance and its use in large-scale clinical trials. *Curr Opin Nephrol Hypertens* 4: 510–513, 1995
14. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI): Clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. *Am J Kidney Dis* 39: S1–S246, 2002
15. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 345: 861–869, 2001
16. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 345: 851–860, 2001
17. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis* 43: S1–S290, 2004
18. Duru OK, Li S, Jurkovitz C, Bakris G, Brown W, Chen SC, Collins A, Klag M, McCullough PA, McGill J, Narva A, Pergola P, Singh A, Norris K: Race and sex differences in hypertension control in CKD: Results from the Kidney Early Evaluation Program (KEEP). *Am J Kidney Dis* 51: 192–198, 2008
19. Parikh NI, Hwang SJ, Larson MG, Meigs JB, Levy D, Fox CS: Cardiovascular disease risk factors in chronic kidney disease: Overall burden and rates of treatment and control. *Arch Intern Med* 166: 1884–1891, 2006
20. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J: The metabolic syndrome and chronic kidney disease in U.S. adults. *Ann Intern Med* 140: 167–174, 2004
21. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D: Predictors of new-onset kidney disease in a community-based population. *JAMA* 291: 844–850, 2004
22. Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D: Obesity and prevalent and incident CKD: The Hypertension Detection and Follow-Up Program. *Am J Kidney Dis* 46: 587–594, 2005

23. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS: Body mass index and risk for end-stage renal disease. *Ann Intern Med* 144: 21–28, 2006
24. Orth SR: Smoking and the kidney. *J Am Soc Nephrol* 13: 1663–1672, 2002
25. Young EW, Mauger EA, Jiang KH, Port FK, Wolfe RA: Socioeconomic status and end-stage renal disease in the United States. *Kidney Int* 45: 907–911, 1994
26. Perneger TV, Whelton PK, Klag MJ: Race and end-stage renal disease: Socioeconomic status and access to health care as mediating factors. *Arch Intern Med* 155: 1201–1208, 1995
27. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J: End-stage renal disease in African-American and white men: 16-year MRFIT findings. *JAMA* 277: 1293–1298, 1997
28. Krop JS, Coresh J, Chambless LE, Shahar E, Watson RL, Szklo M, Brancati FL: A community-based study of explanatory factors for the excess risk for early renal function decline in blacks vs whites with diabetes: The Atherosclerosis Risk in Communities study. *Arch Intern Med* 159: 1777–1783, 1999
29. Merkin SS, Diez Roux AV, Coresh J, Fried LF, Jackson SA, Powe NR: Individual and neighborhood socioeconomic status and progressive chronic kidney disease in an elderly population: The Cardiovascular Health Study. *Soc Sci Med* 65: 809–821, 2007
30. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. *Kidney Int* 51: 1908–1919, 1997
31. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, De Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition—A patient-level meta-analysis. *Ann Intern Med* 139: 244–252, 2003
32. Norris KC, Greene T, Kopple J, Lea J, Lewis J, Lipkowitz M, Miller P, Richardson A, Rostand S, Wang X, Appel LJ: Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. *J Am Soc Nephrol* 17: 2928–2936, 2006
33. Keane WF, Brenner BM, de Zeeuw D, Grunfeld J-P, Lash JP, Lyle PA, McGill J, Mitch WE, Remuzzi G, Shahinfar S, Snapinn SM, Toto R, Zhang Z, RENAAL Study Investigators: A risk score for predicting end-stage renal disease in patients with type 2 diabetes and nephropathy. *Clin J Am Soc Nephrol* 1: 761–767, 2006
34. Culleton BF, Larson MG, Evans JC, Wilson PW, Barrett BJ, Parfrey PS, Levy D: Prevalence and correlates of elevated serum creatinine levels: The Framingham Heart Study. *Arch Intern Med* 159: 1785–1790, 1999
35. Stehman-Breen CO, Gillen D, Steffes M, Jacobs DR Jr, Lewis CE, Kiefe CI, Siscovick D: Racial differences in early-onset renal disease among young adults: The coronary artery risk development in young adults (CARDIA) study. *J Am Soc Nephrol* 14: 2352–2357, 2003
36. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB: Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. *J Am Coll Cardiol* 41: 1364–1372, 2003
37. Muntner P, He J, Astor BC, Folsom AR, Coresh J: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the Atherosclerosis Risk in Communities Study. *J Am Soc Nephrol* 16: 529–538, 2005
38. Patel UD, Young EW, Ojo AO, Hayward RA: CKD progression and mortality among older patients with diabetes. *Am J Kidney Dis* 46: 406–414, 2005
39. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J: The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. *Ann Intern Med* 140: 9–17, 2004
40. National Kidney Foundation Kidney Early Evaluation Program (KEEP) 2006 Annual Data Report. *Am J Kidney Dis* 49: S3–S160, 2007
41. Sika M, Lewis J, Douglas J, Erlinger T, Dowie D, Lipkowitz M, Lash J, Cornish-Zirker D, Peterson G, Toto R, Kusek J, Appel L, Kendrick C, Gassman J: Baseline characteristics of participants in the African American Study of Kidney Disease and Hypertension (AASK) Clinical Trial and Cohort Study. *Am J Kidney Dis* 50: 78–89, 89.e1, 2007
42. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. *JAMA* 288: 2421–2431, 2002
43. Korevaar JC, Merkus MP, Jansen MA, Dekker FW, Boeschoten EW, Krediet RT: Validation of the KDQOL-SF: A dialysis-targeted health measure. *Qual Life Res* 11: 437–447, 2002
44. Diet History Questionnaire, Version 1. National Institutes of Health, Applied Research Program, National Cancer Institute. Available at: <http://riskfactor.cancer.gov/DHQ/>. Accessed June 4, 2009
45. Folstein MF, Folstein SE, McHugh PR: “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 12: 189–198, 1975
46. Rocco MV, Gassman JJ, Wang SR, Kaplan RM: Cross-sectional study of quality of life and symptoms in chronic renal disease patients: The Modification of Diet in Renal Disease Study. *Am J Kidney Dis* 29: 888–896, 1997
47. Beck AT, Steer RA, Garbin MG: Psychometric properties of the Beck Depression Inventory: 25 years of evaluation. *Clin Psychol Rev* 8: 77–100, 1988
48. Ainsworth BE, Irwin ML, Addy CL, Whitt MC, Stolarczyk LM: Moderate physical activity patterns of minority women: The Cross-Cultural Activity Participation Study. *J Womens Health Gend Based Med* 8: 805–813, 1999
49. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, O’Leary D, Saad MF, Shea S, Szklo M, Tracy RP: Multi-ethnic study of atherosclerosis: Objectives and design. *Am J Epidemiol* 156: 871–881, 2002
50. Green CP, Porter CB, Bresnahan DR, Spertus JA: Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure. *J Am Coll Cardiol* 35: 1245–1255, 2000

Appendix B

STATA Output for Baseline Analyses

```

name: <unnamed>
log: R:\CRIC\July_2011\1.1.log
log type: text
opened on: 14 Aug 2011, 07:47:50

```

```
. set more off
```

```
. set linesize 120
```

```
. use "R:\CRIC\July_2011\MS004\ms004_analytical_data_final.dta", clear
```

```
. describe
```

```
Contains data from R:\CRIC\July_2011\MS004\ms004_analytical_data_final.dta
```

```

obs:      3,612
vars:      42
size:     595,980

```

```
-----
```

variable name	storage type	display format	value label	variable label
pid	str8	%8s		pid
TOTAL_PTH	double	%10.0g		Total Parathyroid Hormone
iGFR_baseline	byte	%8.0g	IGFRCOHORT	iGFR subcohort
sex	byte	%8.0g	SEX	
Race_ethnicit~2	byte	%8.0g	RACE_ETHNICITY_CAT2A	Race Ethnicity Category 2
income_cat_1	byte	%8.0g	INCOME_CAT_1A	Income Category 1
edu_cat_1	byte	%8.0g	EDU_CAT_1A	Education Category 1 (categorical)
diabetes_at_b~e	byte	%8.0g	DM	Diabetes at baseline
vnum	byte	%8.0g		vnum
tg	int	%8.0g		Triglycerides
tc	int	%8.0g		Total Cholesterol
hdl	int	%8.0g		High-density Lipoprotein (mg/dL)
ldl	double	%10.0g		Low-density Lipoprotein (mg/dL)
calcium	double	%10.0g		CALCIUM (mg/dL)
glucose	int	%8.0g		GLUCOSE (mg/dL)
HEMOGLOBIN_A1C	double	%10.0g		HEMOGLOBIN_A1C (%)
phosphate	double	%10.0g		PHOSPHATE (mg/dL)
URIC_ACID	double	%10.0g		URIC_ACID (mg/dL)
age	double	%10.0g		Participant Age
smoke100	byte	%8.0g	SMOKE100A	Smoked 100 Cigarettes
smokenow	byte	%8.0g	SMOKENOW	Current Smoker
mirevasc	byte	%8.0g	YESNO	Myocardial Infarction/Prior Revasc (Y/N)
pvd	byte	%8.0g	YESNO	Peripheral Vascular Disease (Y/N)
chf	byte	%8.0g	YESNO	Congestive Heart Failure (Y/N)
weight	double	%10.0g		Weight (kg)
bmi	double	%10.0g		Body Mass Index (kg/m^2)
systolic	double	%10.0g		Systolic BP (mmHg)
diastolic	double	%10.0g		Diastolic BP (mmHg)
hibp	byte	%8.0g	YESNO	High Blood Pressure (Binary)
hypertension	byte	%8.0g	YESNO	Hypertension (y/n)
map	double	%10.0g		Mean Arterial Pressure
CBCHemoglobin	double	%10.0g		CBC Hemoglobin (g/dL)
UPROTEIN24H	double	%10.0g		24H Urine Protein (g/24H)
bmi_cat_2	byte	%8.0g		BMI Category 2
eGFR_Roche	double	%10.0g		Estimated Glomerular Filtration Rate (mg/dL)
eGFR_Roche_cat3	byte	%8.0g	EGFR_ROCHE_CAT3A	eGFR category 3
egfr_roche_ca~e	byte	%8.0g		
scr_roche	double	%10.0g		
acearb	byte	%8.0g		ACE inh or ARB
abicat	byte	%8.0g	ABICAT	Lowest ABI <0.9
race_ethnicit~3	byte	%8.0g	RACE3CAT	
age_screening~t	byte	%8.0g	AGE	categorical age at Screening visit

```
-----
```

Sorted by:

```
. tab diabetes_at_baseline
```

Diabetes at baseline	Freq.	Percent	Cum.
No diabetes	1,927	53.35	53.35
Diabetes	1,685	46.65	100.00
Total	3,612	100.00	

```
. summarize age
```

Variable	Obs	Mean	Std. Dev.	Min	Max
age	3612	58.24859	10.98689	21.15733	75.15342

```
. summarize age if iGFR_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
age	1288	56.12618	12.45532	21.21436	75.15342

```
. summarize age if diabetes_at_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
age	1685	59.53227	9.782761	22.05753	75.14281

```
. summarize age if diabetes_at_baseline==0
```

Variable	Obs	Mean	Std. Dev.	Min	Max
age	1927	57.12612	11.82959	21.15733	75.15342

```
. oneway age diabetes_at_baseline
```

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	5204.53737	1	5204.53737	43.62	0.0000
Within groups	430685.627	3610	119.303498		
Total	435890.164	3611	120.71176		

Bartlett's test for equal variances: $\chi^2(1) = 63.9134$ Prob> $\chi^2 = 0.000$

```
. * tab *
. * tab * if iGFR_baseline==1
. * tab * diabetes_at_baseline, col
.
. * summarize *
. * summarize * if iGFR_baseline==1
. * summarize * if diabetes_at_baseline==1
. * summarize * if diabetes_at_baseline==0
. * oneway * diabetes_at_baseline
.
. tab sex
```

sex	Freq.	Percent	Cum.
Male	1,959	54.24	54.24
Female	1,653	45.76	100.00
Total	3,612	100.00	

```
. tab sex if iGFR_baseline==1
```

sex	Freq.	Percent	Cum.
Male	713	55.36	55.36
Female	575	44.64	100.00
Total	1,288	100.00	

```
. tab sex diabetes_at_baseline, col chi
```

```
+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+
```

sex	Diabetes at baseline		Total
	No diabet	Diabetes	
Male	1,028	931	1,959
	53.35	55.25	54.24
Female	899	754	1,653
	46.65	44.75	45.76
Total	1,927	1,685	3,612
	100.00	100.00	100.00

Pearson chi2(1) = 1.3144 Pr = 0.252

```
. tab Race_ethnicity_cat2
```

Race Ethnicity Category 2	Freq.	Percent	Cum.
Non-Hispanic White	1,638	45.35	45.35
Non-Hispanic Black	1,651	45.71	91.06
Hispanic	169	4.68	95.74
Other	154	4.26	100.00
Total	3,612	100.00	

```
. tab Race_ethnicity_cat2 if iGFR_baseline==1
```

Race Ethnicity Category 2	Freq.	Percent	Cum.
Non-Hispanic White	588	45.65	45.65
Non-Hispanic Black	532	41.30	86.96
Hispanic	69	5.36	92.31
Other	99	7.69	100.00
Total	1,288	100.00	

```
. tab Race_ethnicity_cat2 diabetes_at_baseline, col chi
```

```
+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+
```

Race Ethnicity Category 2	Diabetes at baseline		Total
	No diabet	Diabetes	
Non-Hispanic White	989	649	1,638
	51.32	38.52	45.35

Non-Hispanic Black	802	849	1,651
	41.62	50.39	45.71
Hispanic	58	111	169
	3.01	6.59	4.68
Other	78	76	154
	4.05	4.51	4.26
Total	1,927	1,685	3,612
	100.00	100.00	100.00

Pearson chi2(3) = 72.6716 Pr = 0.000

. tab income_cat_1

Income Category 1	Freq.	Percent	Cum.
\$20,000 or under	1,009	27.93	27.93
\$20,001 - \$50,000	906	25.08	53.02
\$50,000 - \$100,000	725	20.07	73.09
More than \$100,000	389	10.77	83.86
Don't wish to answer	583	16.14	100.00
Total	3,612	100.00	

. tab income_cat_1 if iGFR_baseline==1

Income Category 1	Freq.	Percent	Cum.
\$20,000 or under	297	23.06	23.06
\$20,001 - \$50,000	338	26.24	49.30
\$50,000 - \$100,000	306	23.76	73.06
More than \$100,000	154	11.96	85.02
Don't wish to answer	193	14.98	100.00
Total	1,288	100.00	

. tab income_cat_1 diabetes_at_baseline, col chi

```

+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+

```

Income Category 1	Diabetes at baseline		Total
	No diabet	Diabetes	
\$20,000 or under	444	565	1,009
	23.04	33.53	27.93
\$20,001 - \$50,000	474	432	906
	24.60	25.64	25.08
\$50,000 - \$100,000	444	281	725
	23.04	16.68	20.07
More than \$100,000	253	136	389
	13.13	8.07	10.77
Don't wish to answer	312	271	583
	16.19	16.08	16.14
Total	1,927	1,685	3,612
	100.00	100.00	100.00

Pearson chi2(4) = 75.3022 Pr = 0.000

```
. tab edu_cat_1
```

Education Category 1(categorical)	Freq.	Percent	Cum.
6th grade or less	60	1.66	1.66
7th to 12th grade, no highschool diplom	545	15.09	16.75
High school graduate or equivalent	695	19.25	36.00
Technical or vocational school degree	184	5.10	41.10
Some college education, but not complet	921	25.51	66.60
College graduate	696	19.27	85.88
Professional or graduate degree(e.g. Ma	510	14.12	100.00
Total	3,611	100.00	

```
. tab edu_cat_1, missing
```

Education Category 1(categorical)	Freq.	Percent	Cum.
6th grade or less	60	1.66	1.66
7th to 12th grade, no highschool diplom	545	15.09	16.75
High school graduate or equivalent	695	19.24	35.99
Technical or vocational school degree	184	5.09	41.09
Some college education, but not complet	921	25.50	66.58
College graduate	696	19.27	85.85
Professional or graduate degree(e.g. Ma	510	14.12	99.97
.	1	0.03	100.00
Total	3,612	100.00	

```
. tab edu_cat_1 if iGFR_baseline==1
```

Education Category 1(categorical)	Freq.	Percent	Cum.
6th grade or less	16	1.24	1.24
7th to 12th grade, no highschool diplom	153	11.89	13.13
High school graduate or equivalent	239	18.57	31.70
Technical or vocational school degree	64	4.97	36.67
Some college education, but not complet	319	24.79	61.46
College graduate	298	23.15	84.62
Professional or graduate degree(e.g. Ma	198	15.38	100.00
Total	1,287	100.00	

```
. tab edu_cat_1 diabetes_at_baseline, col chi
```

```
+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+
```

Education Category 1(categorical)	Diabetes at baseline		Total
	No diabet	Diabetes	
6th grade or less	19	41	60
	0.99	2.43	1.66
7th to 12th grade, no	226	319	545
	11.73	18.93	15.09
High school graduate	356	339	695
	18.48	20.12	19.25
Technical or vocation	86	98	184
	4.47	5.82	5.10
Some college educatio	481	440	921
	24.97	26.11	25.51

College graduate	415	281	696
	21.55	16.68	19.27
Professional or gradu	343	167	510
	17.81	9.91	14.12
Total	1,926	1,685	3,611
	100.00	100.00	100.00

Pearson chi2(6) = 97.8475 Pr = 0.000

. tab smokenow

Current Smoker	Freq.	Percent	Cum.
Not current smoker	3,118	86.32	86.32
Yes current smoker	494	13.68	100.00
Total	3,612	100.00	

. tab smokenow if iGFR_baseline==1

Current Smoker	Freq.	Percent	Cum.
Not current smoker	1,136	88.20	88.20
Yes current smoker	152	11.80	100.00
Total	1,288	100.00	

. tab smokenow diabetes_at_baseline, col chi

```

+-----+
| Key   |
+-----+
|       |
| frequency |
| column percentage |
+-----+

```

Current Smoker	Diabetes at baseline		Total
	No diabet	Diabetes	
Not current smoker	1,645	1,473	3,118
	85.37	87.42	86.32
Yes current smoker	282	212	494
	14.63	12.58	13.68
Total	1,927	1,685	3,612
	100.00	100.00	100.00

Pearson chi2(1) = 3.2078 Pr = 0.073

. tab smoke100

Smoked 100 Cigarettes	Freq.	Percent	Cum.
Non-Smoker	1,593	44.10	44.10
Smoker	2,019	55.90	100.00
Total	3,612	100.00	

. tab smoke100 if iGFR_baseline==1

Smoked 100 Cigarettes	Freq.	Percent	Cum.
Non-Smoker	621	48.21	48.21
Smoker	667	51.79	100.00

```
-----+-----
Total |      1,288      100.00
```

```
. tab smoke100 diabetes_at_baseline, col chi
```

```
+-----+
| Key |
|-----|
| frequency |
| column percentage |
+-----+
```

Smoked 100 Cigarettes	Diabetes at baseline		Total
	No diabet	Diabetes	
Non-Smoker	891 46.24	702 41.66	1,593 44.10
Smoker	1,036 53.76	983 58.34	2,019 55.90
Total	1,927 100.00	1,685 100.00	3,612 100.00

Pearson chi2(1) = 7.6356 Pr = 0.006

```
.
. * Generate current smoking variable for subjects who smoked > 100 cigs in lifetime
. * gen smoker = (10*smoke100) + smokenow
. * tab smoker, missing
. * recode smoker(0=.)
. * label define smoker 10"Ex-smoker" 11"Somes Now"
. * label values smoker smoker
. * label var smoker "Currently smoking, excl <100 cigs in life"
. * tab smoker, missing
```

```
. tab hypertension
```

Hypertensio n (y/n)	Freq.	Percent	Cum.
No	516	14.29	14.29
Yes	3,094	85.71	100.00
Total	3,610	100.00	

```
. tab hypertension if iGFR_baseline==1
```

Hypertensio n (y/n)	Freq.	Percent	Cum.
No	197	15.30	15.30
Yes	1,091	84.70	100.00
Total	1,288	100.00	

```
. tab hypertension diabetes_at_baseline, col chi
```

```
+-----+
| Key |
|-----|
| frequency |
| column percentage |
+-----+
```

Hypertensio n (y/n)	Diabetes at baseline		Total
	No diabet	Diabetes	
No	384 19.94	132 7.84	516 14.29

Yes	1,542	1,552	3,094
	80.06	92.16	85.71

Total	1,926	1,684	3,610
	100.00	100.00	100.00

Pearson chi2(1) = 107.3618 Pr = 0.000

. tab mirevasc

Myocardial Infarction/ Prior Revasc (Y/N)	Freq.	Percent	Cum.

No	2,802	77.57	77.57
Yes	810	22.43	100.00

Total	3,612	100.00	

. tab mirevasc if iGFR_baseline==1

Myocardial Infarction/ Prior Revasc (Y/N)	Freq.	Percent	Cum.

No	1,063	82.53	82.53
Yes	225	17.47	100.00

Total	1,288	100.00	

. tab mirevasc diabetes_at_baseline, col chi

```

+-----+
| Key          |
+-----+
| frequency    |
| column percentage |
+-----+

```

Myocardial Infarction /Prior Revasc (Y/N)	Diabetes at baseline		Total
	No diabet	Diabetes	

No	1,610	1,192	2,802
	83.55	70.74	77.57

Yes	317	493	810
	16.45	29.26	22.43

Total	1,927	1,685	3,612
	100.00	100.00	100.00

Pearson chi2(1) = 84.7656 Pr = 0.000

. tab chf

Congestive Heart Failure (Y/N)	Freq.	Percent	Cum.

No	3,255	90.12	90.12
Yes	357	9.88	100.00

```
-----+-----
Total |      3,612      100.00
```

```
. tab chf if iGFR_baseline==1
```

```
Congestive |
Heart |
Failure |
(Y/N) |      Freq.      Percent      Cum.
-----+-----
No |      1,202      93.32      93.32
Yes |         86       6.68      100.00
-----+-----
Total |      1,288      100.00
```

```
. tab chf diabetes_at_baseline, col chi
```

```
+-----+
| Key |
|-----|
| frequency |
| column percentage |
+-----+
```

```
Congestive |
Heart |
Failure | Diabetes at baseline
(Y/N) | No diabet  Diabetes |      Total
-----+-----+-----
No |      1,815      1,440 |      3,255
|      94.19      85.46 |      90.12
-----+-----+-----
Yes |         112         245 |         357
|         5.81        14.54 |         9.88
-----+-----+-----
Total |      1,927      1,685 |      3,612
|      100.00      100.00 |      100.00
```

Pearson chi2(1) = 76.8832 Pr = 0.000

```
. tab pvd
```

```
Peripheral |
Vascular |
Disease |
(Y/N) |      Freq.      Percent      Cum.
-----+-----
No |      3,362      93.08      93.08
Yes |         250       6.92      100.00
-----+-----
Total |      3,612      100.00
```

```
. tab pvd if iGFR_baseline==1
```

```
Peripheral |
Vascular |
Disease |
(Y/N) |      Freq.      Percent      Cum.
-----+-----
No |      1,208      93.79      93.79
Yes |         80       6.21      100.00
-----+-----
Total |      1,288      100.00
```

```
. tab pvd diabetes_at_baseline, col chi
```

```
+-----+
| Key |
|-----|
| frequency |
+-----+
```

```
| column percentage |
+-----+
```

```
Peripheral |
Vascular |
Disease | Diabetes at baseline
(Y/N) | No diabet  Diabetes |      Total
-----+-----+-----+-----+-----+
      No |      1,858      1,504 |      3,362
      |      96.42      89.26 |      93.08
-----+-----+-----+-----+-----+
      Yes |         69         181 |         250
      |         3.58        10.74 |         6.92
-----+-----+-----+-----+-----+
      Total |      1,927      1,685 |      3,612
      |      100.00      100.00 |      100.00
```

Pearson chi2(1) = 71.5577 Pr = 0.000

```
. summarize systolic
```

```
Variable |      Obs      Mean  Std. Dev.  Min  Max
-----+-----+-----+-----+-----+-----+
systolic |    3598  127.6822  21.91062  72.67  242.67
```

```
. summarize systolic if iGFR_baseline==1
```

```
Variable |      Obs      Mean  Std. Dev.  Min  Max
-----+-----+-----+-----+-----+-----+
systolic |    1283  127.8177  21.26446  80.67  219.33
```

```
. summarize systolic if diabetes_at_baseline==1
```

```
Variable |      Obs      Mean  Std. Dev.  Min  Max
-----+-----+-----+-----+-----+-----+
systolic |    1676  132.4087  22.54509  76  242.67
```

```
. summarize systolic if diabetes_at_baseline==0
```

```
Variable |      Obs      Mean  Std. Dev.  Min  Max
-----+-----+-----+-----+-----+-----+
systolic |    1922  123.5606  20.47546  72.67  214
```

```
. oneway  systolic diabetes_at_baseline
```

```
          Analysis of Variance
Source          SS      df      MS          F      Prob > F
-----+-----+-----+-----+-----+-----+
Between groups  70092.3267      1  70092.3267  152.14  0.0000
Within groups  1656739.09  3596   460.71721
-----+-----+-----+-----+-----+
Total          1726831.41  3597   480.075455
```

Bartlett's test for equal variances: chi2(1) = 16.6354 Prob>chi2 = 0.000

```
. summarize diastolic
```

```
Variable |      Obs      Mean  Std. Dev.  Min  Max
-----+-----+-----+-----+-----+-----+
diastolic |    3593   71.3915  12.81669  34  138.67
```

```
. summarize diastolic if iGFR_baseline==1
```

```
Variable |      Obs      Mean  Std. Dev.  Min  Max
-----+-----+-----+-----+-----+-----+
diastolic |    1282   72.38408  12.65465  39.33  116
```

```
. summarize diastolic if diabetes_at_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
diastolic	1673	69.39751	12.75837	34	138.67

. summarize diastolic if diabetes_at_baseline==0

Variable	Obs	Mean	Std. Dev.	Min	Max
diastolic	1920	73.12897	12.6161	35.33	138.67

. oneway diastolic diabetes_at_baseline

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	12447.91	1	12447.91	77.39	0.0000
Within groups	577601.013	3591	160.846843		
Total	590048.923	3592	164.267518		

Bartlett's test for equal variances: chi2(1) = 0.2248 Prob>chi2 = 0.635

. summarize map

Variable	Obs	Mean	Std. Dev.	Min	Max
map	3593	90.15213	13.76471	53.78	161.78

. summarize map if iGFR_baseline==1

Variable	Obs	Mean	Std. Dev.	Min	Max
map	1282	90.85255	13.21406	57.11333	145.1133

. summarize map if diabetes_at_baseline==1

Variable	Obs	Mean	Std. Dev.	Min	Max
map	1673	90.40123	13.93872	56.66667	161.78

. summarize map if diabetes_at_baseline==0

Variable	Obs	Mean	Std. Dev.	Min	Max
map	1920	89.93508	13.61119	53.78	160.4467

. oneway map diabetes_at_baseline

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	194.269325	1	194.269325	1.03	0.3113
Within groups	680371.822	3591	189.465837		
Total	680566.091	3592	189.467175		

Bartlett's test for equal variances: chi2(1) = 1.0111 Prob>chi2 = 0.315

. tab hibp

High Blood Pressure (Binary)	Freq.	Percent	Cum.
No	1,912	53.14	53.14
Yes	1,686	46.86	100.00
Total	3,598	100.00	

```
. tab hibp if iGFR_baseline==1
```

High Blood Pressure (Binary)	Freq.	Percent	Cum.
No	657	51.21	51.21
Yes	626	48.79	100.00
Total	1,283	100.00	

```
. tab hibp diabetes_at_baseline, col chi
```

```
+-----+
| Key |
|-----|
| frequency |
| column percentage |
+-----+
```

High Blood Pressure (Binary)	Diabetes at baseline		Total
	No diabet	Diabetes	
No	1,118	794	1,912
	58.17	47.37	53.14
Yes	804	882	1,686
	41.83	52.63	46.86
Total	1,922	1,676	3,598
	100.00	100.00	100.00

Pearson chi2(1) = 41.8888 Pr = 0.000

```
. summarize weight
```

Variable	Obs	Mean	Std. Dev.	Min	Max
weight	3606	92.0198	23.67658	32.4	220.9

```
. summarize weight if iGFR_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
weight	1288	89.88773	21.19833	40.2	195.1

```
. summarize weight if diabetes_at_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
weight	1680	97.69393	24.19955	40.2	206.6

```
. summarize weight if diabetes_at_baseline==0
```

Variable	Obs	Mean	Std. Dev.	Min	Max
weight	1926	87.0704	22.05507	32.4	220.9

```
. oneway weight diabetes_at_baseline
```

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	101269.115	1	101269.115	190.13	0.0000
Within groups	1919623.15	3604	532.636834		
Total	2020892.27	3605	560.580379		

Bartlett's test for equal variances: chi2(1) = 15.4822 Prob>chi2 = 0.000

```
. summarize bmi
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	3602	32.07927	7.925037	14.59011	88.01366

```
. summarize bmi if igFR_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	1287	31.29089	6.973046	15.41241	73.75553

```
. summarize bmi if diabetes_at_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	1678	34.14999	8.226703	15.99768	88.01366

```
. summarize bmi if diabetes_at_baseline==0
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	1924	30.27332	7.182269	14.59011	82.83681

```
. oneway bmi diabetes_at_baseline
```

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	13470.1511	1	13470.1511	227.99	0.0000
Within groups	212695.034	3600	59.0819539		
Total	226165.185	3601	62.8062164		

Bartlett's test for equal variances: $\chi^2(1) = 33.1193$ Prob> $\chi^2 = 0.000$

```
. bysort bmi_cat_2: summarize bmi
```

```
-> bmi_cat_2 = 1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	597	22.44584	2.023514	14.59011	24.99901

```
-> bmi_cat_2 = 2
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	1018	27.62509	1.408869	25.00499	29.99784

```
-> bmi_cat_2 = 3
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	1987	37.25568	6.83807	30.0073	88.01366

```
. label define bmi_cat_2 1"<25" 2"25-30" 3">30"
```

```
. label values bmi_cat_2 bmi_cat_2
```

```
. tab bmi_cat_2
```

BMI Category 2	Freq.	Percent	Cum.
<25	607	16.81	16.81
25-30	1,018	28.18	44.99
>30	1,987	55.01	100.00
Total	3,612	100.00	

. tab bmi_cat_2 if iGFR_baseline==1

BMI Category 2	Freq.	Percent	Cum.
<25	234	18.17	18.17
25-30	381	29.58	47.75
>30	673	52.25	100.00
Total	1,288	100.00	

. tab bmi_cat_2 diabetes_at_baseline, col chi

```

+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+

```

BMI Diabetes at baseline Category 2	No diabet	Diabetes	Total
<25	428	179	607
	22.21	10.62	16.81
25-30	630	388	1,018
	32.69	23.03	28.18
>30	869	1,118	1,987
	45.10	66.35	55.01
Total	1,927	1,685	3,612
	100.00	100.00	100.00

Pearson chi2(2) = 175.4490 Pr = 0.000

. tab abicat

Lowest ABI <0.9	Freq.	Percent	Cum.
>=0.9	2,976	83.60	83.60
<0.9	584	16.40	100.00
Total	3,560	100.00	

. tab abicat if iGFR_baseline==1

Lowest ABI <0.9	Freq.	Percent	Cum.
>=0.9	1,082	84.80	84.80
<0.9	194	15.20	100.00
Total	1,276	100.00	

. tab abicat diabetes_at_baseline, col chi

```

+-----+
| Key |

```

```

+-----+
| frequency |
| column percentage |
+-----+

```

Lowest ABI	Diabetes at baseline		Total
<0.9	No diabet	Diabetes	
>=0.9	1,701	1,275	2,976
	88.87	77.46	83.60
<0.9	213	371	584
	11.13	22.54	16.40
Total	1,914	1,646	3,560
	100.00	100.00	100.00

Pearson chi2(1) = 84.0273 Pr = 0.000

```
. summarize scr_roche
```

Variable	Obs	Mean	Std. Dev.	Min	Max
scr_roche	3596	1.729818	.5705031	.54885	7.85751

```
. summarize scr_roche if iGFR_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
scr_roche	1286	1.680576	.5621269	.63798	4.38144

```
. summarize scr_roche if diabetes_at_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
scr_roche	1679	1.803252	.5647991	.54885	4.38144

```
. summarize scr_roche if diabetes_at_baseline==0
```

Variable	Obs	Mean	Std. Dev.	Min	Max
scr_roche	1917	1.665501	.5678475	.63798	7.85751

```
. oneway scr_roche diabetes_at_baseline
```

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	16.9840245	1	16.9840245	52.94	0.0000
Within groups	1153.09438	3594	.320838726		
Total	1170.0784	3595	.325473826		

Bartlett's test for equal variances: chi2(1) = 0.0518 Prob>chi2 = 0.820

```
. summarize eGFR_Roche
```

Variable	Obs	Mean	Std. Dev.	Min	Max
eGFR_Roche	3596	43.39008	13.51411	7.004488	113.9882

```
. summarize eGFR_Roche if iGFR_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
eGFR_Roche	1286	45.17029	14.0768	13.43334	97.82357

```
. summarize eGFR_Roche if diabetes_at_baseline==1
```


Variable	Obs	Mean	Std. Dev.	Min	Max
eGFR_Roche	1679	41.4218	12.93277	13.43334	113.9882

. summarize eGFR_Roche if diabetes_at_baseline==0

Variable	Obs	Mean	Std. Dev.	Min	Max
eGFR_Roche	1917	45.11399	13.77763	7.004488	93.68277

. oneway eGFR_Roche diabetes_at_baseline

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	12201.7063	1	12201.7063	68.06	0.0000
Within groups	644357.701	3594	179.287062		
Total	656559.407	3595	182.631268		

Bartlett's test for equal variances: chi2(1) = 7.1380 Prob>chi2 = 0.008

. tab eGFR_Roche_cat3

eGFR category 3	Freq.	Percent	Cum.
less than 15	3	0.08	0.08
15 to less than 30	664	18.46	18.55
30 to less than 60	2,532	70.41	88.96
60 to less than 90	389	10.82	99.78
Greater than 90	8	0.22	100.00
Total	3,596	100.00	

. tab eGFR_Roche_cat3 if iGFR==1

eGFR category 3	Freq.	Percent	Cum.
less than 15	2	0.16	0.16
15 to less than 30	206	16.02	16.17
30 to less than 60	887	68.97	85.15
60 to less than 90	187	14.54	99.69
Greater than 90	4	0.31	100.00
Total	1,286	100.00	

. tab eGFR_Roche_cat3 diabetes_at_baseline, col chi

eGFR category 3	Diabetes at baseline		Total
	No diabet	Diabetes	
less than 15	2	1	3
	0.10	0.06	0.08
15 to less than 30	313	351	664
	16.33	20.91	18.46
30 to less than 60	1,335	1,197	2,532
	69.64	71.29	70.41
60 to less than 90	263	126	389
	13.72	7.50	10.82

Greater than 90	4	4	8
	0.21	0.24	0.22
-----+-----+-----			
Total	1,917	1,679	3,596
	100.00	100.00	100.00

Pearson chi2(4) = 42.7139 Pr = 0.000

. summarize UPROTEIN24H, detail

24H Urine Protein (g/24H)

Percentiles		Smallest		
1%	.0216	.0076755		
5%	.035233	.01275		
10%	.0462	.013	Obs	3424
25%	.072	.0138	Sum of Wgt.	3424
50%			Mean	.9644493
	.1700089		Std. Dev.	2.163381
		Largest		
75%	.8066043	20.10376	Variance	4.680217
90%	2.68424	21.528	Skewness	5.012783
95%	4.385258	23.8038	Kurtosis	37.9539
99%	11.9328	30.11958		

. summarize UPROTEIN24H if iGFR_baseline==1, detail

24H Urine Protein (g/24H)

Percentiles		Smallest		
1%	.0206897	.0076755		
5%	.03265	.01275		
10%	.04635	.013	Obs	1228
25%	.0748787	.0145895	Sum of Wgt.	1228
50%			Mean	1.048534
	.1829864		Std. Dev.	2.219347
		Largest		
75%	.8973083	17.313	Variance	4.925502
90%	3.0932	17.7375	Skewness	4.248602
95%	4.739745	20.05677	Kurtosis	25.96647
99%	12.1771	20.10376		

. summarize UPROTEIN24H if diabetes_at_baseline==1, detail

24H Urine Protein (g/24H)

Percentiles		Smallest		
1%	.0232727	.01275		
5%	.0411	.0138		
10%	.054	.0169412	Obs	1593
25%	.0924642	.0171636	Sum of Wgt.	1593
50%			Mean	1.428979
	.323103		Std. Dev.	2.782309
		Largest		
75%	1.485453	20.10376	Variance	7.741246
90%	3.865888	21.528	Skewness	4.006219
95%	6.59932	23.8038	Kurtosis	24.47604
99%	14.82	30.11958		

. summarize UPROTEIN24H if diabetes_at_baseline==0, detail

24H Urine Protein (g/24H)

Percentiles		Smallest		
1%	.0196129	.0076755		
5%	.0314449	.013		
10%	.0426762	.0145895	Obs	1831
25%	.0628	.0159319	Sum of Wgt.	1831
50%			Mean	.5603008

```

Largest      Std. Dev.      1.291735
75%          .4294531      11.144
90%          1.482        14.1218      Variance      1.668579
95%          2.8044       15.8556      Skewness      5.799735
99%          6.394        18.90536     Kurtosis      53.80757

```

```
. oneway UPROTEIN24H diabetes_at_baseline
```

```

Analysis of Variance
Source          SS          df          MS          F          Prob > F
-----
Between groups  642.8182     1          642.8182    143.05     0.0000
Within groups  15377.5632  3422       4.4937356
-----
Total          16020.3814  3423       4.6802166

```

```
Bartlett's test for equal variances:  chi2(1) = 946.8702  Prob>chi2 = 0.000
```

```
. label values acearb YESNO
```

```
. tab acearb
```

```

ACE inh or |
ARB |      Freq.      Percent      Cum.
-----+-----
No |      1,150      31.84      31.84
Yes |      2,462      68.16      100.00
-----+-----
Total |      3,612      100.00

```

```
. tab acearb if iGFR_baseline==1
```

```

ACE inh or |
ARB |      Freq.      Percent      Cum.
-----+-----
No |         408      31.68      31.68
Yes |         880      68.32      100.00
-----+-----
Total |      1,288      100.00

```

```
. tab acearb diabetes_at_baseline, col chi
```

```

+-----+
| Key |
|-----|
| frequency |
| column percentage |
+-----+

ACE inh or | Diabetes at baseline
ARB | No diabet  Diabetes |      Total
-----+-----+-----
No |      801      349 |      1,150
|      41.57      20.71 |      31.84
-----+-----+-----
Yes |      1,126      1,336 |      2,462
|      58.43      79.29 |      68.16
-----+-----+-----
Total |      1,927      1,685 |      3,612
|      100.00      100.00 |      100.00

```

```
Pearson chi2(1) = 180.1629  Pr = 0.000
```

```
. summarize tc
```

```

Variable |      Obs      Mean      Std. Dev.      Min      Max
-----+-----
tc |      3602      183.0564      44.52696      76      571

```

```
. summarize tc if iGFR_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
tc	1288	183.6266	46.98261	77	571

```
. summarize tc if diabetes_at_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
tc	1682	176.9762	47.07712	76	571

```
. summarize tc if diabetes_at_baseline==0
```

Variable	Obs	Mean	Std. Dev.	Min	Max
tc	1920	188.3828	41.45193	77	436

```
. oneway tc diabetes_at_baseline
```

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	116652.878	1	116652.878	59.80	0.0000
Within groups	7022870.68	3600	1950.79741		
Total	7139523.56	3601	1982.65025		

Bartlett's test for equal variances: $\chi^2(1) = 29.0971$ Prob> $\chi^2 = 0.000$

```
. summarize ldl
```

Variable	Obs	Mean	Std. Dev.	Min	Max
ldl	3597	102.6336	35.25909	15	295

```
. summarize ldl if iGFR_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
ldl	1287	103.4336	36.50073	15	250

```
. summarize ldl if diabetes_at_baseline==1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
ldl	1677	96.43172	35.42517	15	264

```
. summarize ldl if diabetes_at_baseline==0
```

Variable	Obs	Mean	Std. Dev.	Min	Max
ldl	1920	108.0505	34.21443	21	295

```
. oneway ldl diabetes_at_baseline
```

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	120841.531	1	120841.531	99.87	0.0000
Within groups	4349717.21	3595	1209.93525		
Total	4470558.74	3596	1243.20321		

Bartlett's test for equal variances: $\chi^2(1) = 2.1661$ Prob> $\chi^2 = 0.141$

```
. summarize hdl
```

Variable	Obs	Mean	Std. Dev.	Min	Max
----------	-----	------	-----------	-----	-----

```
-----+-----
      hdl |      3602      48.05719      15.60109           8           170
```

```
. summarize hdl if iGFR_baseline==1
```

```
-----+-----
Variable |      Obs      Mean      Std. Dev.      Min      Max
-----+-----
      hdl |     1288     47.46118     15.66952           8     162
```

```
. summarize hdl if diabetes_at_baseline==1
```

```
-----+-----
Variable |      Obs      Mean      Std. Dev.      Min      Max
-----+-----
      hdl |     1682     45.69084     13.85682           8     122
```

```
. summarize hdl if diabetes_at_baseline==0
```

```
-----+-----
Variable |      Obs      Mean      Std. Dev.      Min      Max
-----+-----
      hdl |     1920     50.13021     16.71297          12     170
```

```
. oneway hdl diabetes_at_baseline
```

Analysis of Variance					
Source	SS	df	MS	F	Prob > F
Between groups	17669.5318	1	17669.5318	74.07	0.0000
Within groups	858792.687	3600	238.553524		
Total	876462.219	3601	243.394118		

```
Bartlett's test for equal variances: chi2(1) = 62.0521 Prob>chi2 = 0.000
```

```
. summarize tg
```

```
-----+-----
Variable |      Obs      Mean      Std. Dev.      Min      Max
-----+-----
      tg |     3602     153.6891     115.1501          31     1755
```

```
. summarize tg if iGFR_baseline==1
```

```
-----+-----
Variable |      Obs      Mean      Std. Dev.      Min      Max
-----+-----
      tg |     1288     151.5054     111.9152          31     1509
```

```
. summarize tg if diabetes_at_baseline==1
```

```
-----+-----
Variable |      Obs      Mean      Std. Dev.      Min      Max
-----+-----
      tg |     1682     165.9507     129.8402          31     1755
```

```
. summarize tg if diabetes_at_baseline==0
```

```
-----+-----
Variable |      Obs      Mean      Std. Dev.      Min      Max
-----+-----
      tg |     1920     142.9474     99.33092          31     1509
```

```
. oneway tg diabetes_at_baseline
```

Analysis of Variance					
Source	SS	df	MS	F	Prob > F
Between groups	474419.158	1	474419.158	36.13	0.0000
Within groups	47273170.6	3600	13131.4363		
Total	47747589.7	3601	13259.5362		

```
Bartlett's test for equal variances: chi2(1) = 128.5223 Prob>chi2 = 0.000
```

. summarize CBCHemoglobin

Variable	Obs	Mean	Std. Dev.	Min	Max
CBCHemoglo~n	3570	12.6628	1.766184	5.3	18.9

. summarize CBCHemoglobin if iGFR_baseline==1

Variable	Obs	Mean	Std. Dev.	Min	Max
CBCHemoglo~n	1280	12.64703	1.742593	5.3	18.9

. summarize CBCHemoglobin if diabetes_at_baseline==1

Variable	Obs	Mean	Std. Dev.	Min	Max
CBCHemoglo~n	1662	12.09759	1.674858	6.6	18.9

. summarize CBCHemoglobin if diabetes_at_baseline==0

Variable	Obs	Mean	Std. Dev.	Min	Max
CBCHemoglo~n	1908	13.15514	1.695235	5.3	18.9

. oneway CBCHemoglobin diabetes_at_baseline

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	993.429951	1	993.429951	349.57	0.0000
Within groups	10139.73	3568	2.84185259		
Total	11133.16	3569	3.11940599		

Bartlett's test for equal variances: chi2(1) = 0.2594 Prob>chi2 = 0.610

. summarize calcium

Variable	Obs	Mean	Std. Dev.	Min	Max
calcium	3581	9.198855	.501268	5.8	11.7

. summarize calcium if iGFR_baseline==1

Variable	Obs	Mean	Std. Dev.	Min	Max
calcium	1281	9.179938	.5184369	5.8	11.3

. summarize calcium if diabetes_at_baseline==1

Variable	Obs	Mean	Std. Dev.	Min	Max
calcium	1675	9.147104	.5139008	6.3	11.3

. summarize calcium if diabetes_at_baseline==0

Variable	Obs	Mean	Std. Dev.	Min	Max
calcium	1906	9.244334	.4854977	5.8	11.7

. oneway calcium diabetes_at_baseline

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	8.42804529	1	8.42804529	33.85	0.0000
Within groups	891.11726	3579	.248984985		
Total	899.545306	3580	.251269638		

Bartlett's test for equal variances: chi2(1) = 5.7700 Prob>chi2 = 0.016

. summarize phosphate

Variable	Obs	Mean	Std. Dev.	Min	Max
phosphate	3549	3.704706	.6605043	1.7	9.3

. summarize phosphate if iGFR_baseline==1

Variable	Obs	Mean	Std. Dev.	Min	Max
phosphate	1253	3.68755	.6658523	1.7	9.3

. summarize phosphate if diabetes_at_baseline==1

Variable	Obs	Mean	Std. Dev.	Min	Max
phosphate	1660	3.881386	.6999418	1.8	9.3

. summarize phosphate if diabetes_at_baseline==0

Variable	Obs	Mean	Std. Dev.	Min	Max
phosphate	1889	3.549444	.5811945	1.7	7

. oneway phosphate diabetes_at_baseline

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	97.3546877	1	97.3546877	238.06	0.0000
Within groups	1450.51673	3547	.408941847		
Total	1547.87142	3548	.436265901		

Bartlett's test for equal variances: chi2(1) = 61.1626 Prob>chi2 = 0.000

. * NOTE this is TOTAL not INACTIVE contrary to footnote in published table
 . summarize TOTAL_PTH, detail

Total Parathyroid Hormone				
Percentiles		Smallest		
1%	12	1.9		
5%	20	3		
10%	24.5	6.9	Obs	3495
25%	34	7	Sum of Wgt.	3495
50%	53		Mean	74.47542
		Largest	Std. Dev.	72.52342
75%	88	729.4		
90%	148.3	741	Variance	5259.647
95%	197.7	931	Skewness	5.28305
99%	330	1483	Kurtosis	63.01433

. summarize TOTAL_PTH if iGFR_baseline==1, detail

Total Parathyroid Hormone				
Percentiles		Smallest		
1%	12	3		
5%	19.9	6.9		
10%	24.25	7.9	Obs	1250
25%	34	8	Sum of Wgt.	1250
50%	52.85		Mean	72.63952
		Largest	Std. Dev.	75.66136
75%	85	602		

90%	142	606	Variance	5724.642
95%	184.7	729.4	Skewness	7.357504
99%	330	1483	Kurtosis	109.3378

. summarize TOTAL_PTH if diabetes_at_baseline==1, detail

Total Parathyroid Hormone

	Percentiles	Smallest		
1%	11.4	3		
5%	19	7		
10%	24.7	7	Obs	1634
25%	37.1	8	Sum of Wgt.	1634
50%	59.95		Mean	81.23513
		Largest	Std. Dev.	79.39427
75%	102.4	633.2		
90%	158.8	741	Variance	6303.449
95%	209.3	931	Skewness	6.00783
99%	319.9	1483	Kurtosis	78.10269

. summarize TOTAL_PTH if diabetes_at_baseline==0, detail

Total Parathyroid Hormone

	Percentiles	Smallest		
1%	13	1.9		
5%	20.6	6.9		
10%	24.5	7.9	Obs	1861
25%	32.5	8.1	Sum of Wgt.	1861
50%	48.5		Mean	68.54025
		Largest	Std. Dev.	65.35039
75%	78	615.3		
90%	131.1	659.1	Variance	4270.674
95%	185	678	Skewness	3.97774
99%	339	729.4	Kurtosis	27.61437

. oneway TOTAL_PTH diabetes_at_baseline

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	140219.54	1	140219.54	26.86	0.0000
Within groups	18236986.1	3493	5221.00947		
Total	18377205.6	3494	5259.64671		

Bartlett's test for equal variances: chi2(1) = 66.0233 Prob>chi2 = 0.000

. summarize glucose, detail

GLUCOSE (mg/dL)

	Percentiles	Smallest		
1%	58	31		
5%	73	36		
10%	79	36	Obs	3578
25%	86	42	Sum of Wgt.	3578
50%	97		Mean	114.4782
		Largest	Std. Dev.	51.62496
75%	124	522		
90%	173	545	Variance	2665.136
95%	214	582	Skewness	3.099169
99%	315	596	Kurtosis	17.62465

. summarize glucose if iGFR_baseline==1, detail

GLUCOSE (mg/dL)


```
-----
```

	Percentiles	Smallest		
1%	58	36		
5%	72	36		
10%	78	44	Obs	1281
25%	86	46	Sum of Wgt.	1281
50%	97		Mean	111.3856
		Largest	Std. Dev.	48.43131
75%	121	447		
90%	159	450	Variance	2345.592
95%	198	519	Skewness	3.573956
99%	318	596	Kurtosis	23.02712

. summarize glucose if diabetes_at_baseline==1, detail

```
-----
```

GLUCOSE (mg/dL)

```
-----
```

	Percentiles	Smallest		
1%	49	31		
5%	69	36		
10%	80	36	Obs	1673
25%	100	42	Sum of Wgt.	1673
50%	127		Mean	140.7454
		Largest	Std. Dev.	65.20376
75%	163	522		
90%	218	545	Variance	4251.531
95%	268	582	Skewness	2.101816
99%	382	596	Kurtosis	10.3886

. summarize glucose if diabetes_at_baseline==0, detail

```
-----
```

GLUCOSE (mg/dL)

```
-----
```

	Percentiles	Smallest		
1%	69	42		
5%	75	56		
10%	78	58	Obs	1905
25%	84	62	Sum of Wgt.	1905
50%	90		Mean	91.40997
		Largest	Std. Dev.	11.60879
75%	98	125		
90%	107	133	Variance	134.7641
95%	114	147	Skewness	.6015227
99%	123	160	Kurtosis	4.172219

. oneway glucose diabetes_at_baseline

Analysis of Variance					
Source	SS	df	MS	F	Prob > F
Between groups	2168042.46	1	2168042.46	1052.65	0.0000
Within groups	7365150.34	3576	2059.6058		
Total	9533192.8	3577	2665.13637		

Bartlett's test for equal variances: chi2(1) = 4.0e+03 Prob>chi2 = 0.000

. *
 . * Shouldn't this be a nonparametric test ??????????
 . *

. summarize HEMOGLOBIN_A1C

Variable	Obs	Mean	Std. Dev.	Min	Max
HEMOGLOBI~1C	3546	6.629583	1.56183	3.5	18.3

. summarize HEMOGLOBIN_A1C if iGFR_baseline==1

Variable	Obs	Mean	Std. Dev.	Min	Max
HEMOGLOBI~1C	1272	6.544969	1.613205	3.5	18.3

. summarize HEMOGLOBIN_A1C if diabetes_at_baseline==1

Variable	Obs	Mean	Std. Dev.	Min	Max
HEMOGLOBI~1C	1668	7.673621	1.67346	4.4	18.3

. summarize HEMOGLOBIN_A1C if diabetes_at_baseline==0

Variable	Obs	Mean	Std. Dev.	Min	Max
HEMOGLOBI~1C	1878	5.70229	.539342	3.5	8.5

. oneway HEMOGLOBIN_A1C diabetes_at_baseline

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	3432.9873	1	3432.9873	2333.26	0.0000
Within groups	5214.37948	3544	1.47132604		
Total	8647.36678	3545	2.43931362		

Bartlett's test for equal variances: chi2(1) = 2.0e+03 Prob>chi2 = 0.000

.
end of do-file

. log close
name: <unnamed>
log: R:\CRIC\July_2011\1.log
log type: text
closed on: 14 Aug 2011, 07:48:16

```

-----
name: <unnamed>
log: R:\CRIC\July_2011\MS004\2.log
log type: text
opened on: 14 Aug 2011, 08:49:52

```

```
. set more off
```

```
. set linesize 120
```

```
. use "R:\CRIC\July_2011\MS004\ms004_analytical_data_final.dta", clear
```

```
. describe
```

```
Contains data from R:\CRIC\July_2011\MS004\ms004_analytical_data_final.dta
```

```

obs:      3,612
vars:      42
size:     595,980

```

```

-----
variable name   storage   display   value   variable label
                type     format    label
-----
pid             str8      %8s                pid
TOTAL_PTH       double   %10.0g           Total Parathyroid Hormone
iGFR_baseline  byte     %8.0g            IGFRCOHORT
                                iGFR subcohort
sex             byte     %8.0g            SEX
Race_ethnicit~2 byte     %8.0g           RACE_ETHNICITY_CAT2A
                                Race Ethnicity Category 2
income_cat_1    byte     %8.0g           INCOME_CAT_1A
                                Income Category 1
edu_cat_1       byte     %8.0g           EDU_CAT_1A
                                Education Category 1 (categorical)
diabetes_at_b~e byte     %8.0g           DM
                                Diabetes at baseline
vnum            byte     %8.0g           vnum
                                Triglycerides
tg              int      %8.0g           tc
                                Total Cholesterol
tc              int      %8.0g           hdl
                                High-density Lipoprotein (mg/dL)
hdl             int      %8.0g           ldl
                                Low-density Lipoprotein (mg/dL)
calcium         double   %10.0g          CALCIUM (mg/dL)
glucose         int      %8.0g           GLUCOSE (mg/dL)
HEMOGLOBIN_A1C double   %10.0g          HEMOGLOBIN_A1C (%)
phosphate       double   %10.0g          PHOSPHATE (mg/dL)
URIC_ACID       double   %10.0g          URIC_ACID (mg/dL)
age             double   %10.0g          Participant Age
smoke100        byte     %8.0g           SMOKE100A
                                Smoked 100 Cigarettes
smokenow        byte     %8.0g           SMOKENOW
                                Current Smoker
mirevasc        byte     %8.0g           YESNO
                                Myocardial Infarction/Prior Revasc (Y/N)
pvd             byte     %8.0g           YESNO
                                Peripheral Vascular Disease (Y/N)
chf             byte     %8.0g           YESNO
                                Congestive Heart Failure (Y/N)
weight          double   %10.0g          Weight (kg)
bmi             double   %10.0g          Body Mass Index (kg/m^2)
systolic        double   %10.0g          Systolic BP (mmHg)
diastolic       double   %10.0g          Diastolic BP (mmHg)
hibp            byte     %8.0g           YESNO
                                High Blood Pressure (Binary)
hypertension    byte     %8.0g           YESNO
                                Hypertension (y/n)
map             double   %10.0g          Mean Arterial Pressure
CBCHemoglobin   double   %10.0g          CBC Hemoglobin (g/dL)
UPROTEIN24H     double   %10.0g          24H Urine Protein (g/24H)
bmi_cat_2       byte     %8.0g           BMI Category 2
eGFR_Roche      double   %10.0g          Estimated Glomerular Filtration Rate (mg/dL)
eGFR_Roche_cat3 byte     %8.0g           EGFR_ROCHE_CAT3A
                                eGFR category 3
egfr_roche_ca~e byte     %8.0g
scr_roche        double   %10.0g
acearb          byte     %8.0g           ACE inh or ARB
abicat          byte     %8.0g           ABICAT
                                Lowest ABI <0.9

```

```

race_ethnicit~3 byte  %8.0g      RACE3CAT
age_screening~t byte  %8.0g      AGE      categorical age at Screening visit
-----

```

Sorted by:

```

. by egfr_roche_cat_baseline, sort: summarize age
-----

```

```

-> egfr_roche_cat_baseline = 1

```

Variable	Obs	Mean	Std. Dev.	Min	Max
age	667	58.68254	11.23854	22.05073	75.0411

```

-----
-> egfr_roche_cat_baseline = 2

```

Variable	Obs	Mean	Std. Dev.	Min	Max
age	844	59.6301	10.95116	21.66849	74.98475

```

-----
-> egfr_roche_cat_baseline = 3

```

Variable	Obs	Mean	Std. Dev.	Min	Max
age	968	60.01629	10.37942	21.15733	75.14281

```

-----
-> egfr_roche_cat_baseline = 4

```

Variable	Obs	Mean	Std. Dev.	Min	Max
age	720	57.67078	10.13529	21.80899	75.15342

```

-----
-> egfr_roche_cat_baseline = 5

```

Variable	Obs	Mean	Std. Dev.	Min	Max
age	397	51.53377	10.97019	21.21436	74.84932

```

-----
-> egfr_roche_cat_baseline = .

```

Variable	Obs	Mean	Std. Dev.	Min	Max
age	16	52.95027	10.41931	33.40877	68.05479

```

. oneway age egfr_roche_cat_baseline

```

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	22899.8292	4	5724.95729	50.03	0.0000
Within groups	410910.751	3591	114.427945		
Total	433810.58	3595	120.670537		

```

Bartlett's test for equal variances:  chi2(4) = 10.5679  Prob>chi2 = 0.032

```

```

. tab sex egfr_roche_cat_baseline, col chi

```

Key

```

| frequency |
| column percentage |
+-----+

```

sex	egfr_roche_cat_baseline					Total
	1	2	3	4	5	
Male	311	440	568	406	226	1,951
	46.63	52.13	58.68	56.39	56.93	54.25
Female	356	404	400	314	171	1,645
	53.37	47.87	41.32	43.61	43.07	45.75
Total	667	844	968	720	397	3,596
	100.00	100.00	100.00	100.00	100.00	100.00

Pearson chi2(4) = 27.2622 Pr = 0.000

```
. tab Race_ethnicity_cat2 egfr_roche_cat_baseline, col chi
```

```

+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+

```

Race Ethnicity Category 2	egfr_roche_cat_baseline					Total
	1	2	3	4	5	
Non-Hispanic White	277	386	461	348	160	1,632
	41.53	45.73	47.62	48.33	40.30	45.38
Non-Hispanic Black	303	387	430	319	202	1,641
	45.43	45.85	44.42	44.31	50.88	45.63
Hispanic	55	43	32	21	18	169
	8.25	5.09	3.31	2.92	4.53	4.70
Other	32	28	45	32	17	154
	4.80	3.32	4.65	4.44	4.28	4.28
Total	667	844	968	720	397	3,596
	100.00	100.00	100.00	100.00	100.00	100.00

Pearson chi2(12) = 39.5364 Pr = 0.000

```
. tab income_cat_1 egfr_roche_cat_baseline, col chi
```

```

+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+

```

Income Category 1	egfr_roche_cat_baseline					Total
	1	2	3	4	5	
\$20,000 or under	249	292	232	155	72	1,000
	37.33	34.60	23.97	21.53	18.14	27.81
\$20,001 - \$50,000	179	199	267	162	96	903
	26.84	23.58	27.58	22.50	24.18	25.11
\$50,000 - \$100,000	108	150	187	171	108	724
	16.19	17.77	19.32	23.75	27.20	20.13
More than \$100,000	38	69	117	115	49	388

	5.70	8.18	12.09	15.97	12.34	10.79
Don't wish to answer	93	134	165	117	72	581
	13.94	15.88	17.05	16.25	18.14	16.16
Total	667	844	968	720	397	3,596
	100.00	100.00	100.00	100.00	100.00	100.00

Pearson chi2(16) = 138.0111 Pr = 0.000

. tab edu_cat_1 egfr_roche_cat_baseline, col chi

```

+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+

```

Education Category 1 (categorical)	egfr_roche_cat_baseline					Total
	1	2	3	4	5	
6th grade or less	27	15	10	4	4	60
	4.05	1.78	1.03	0.56	1.01	1.67
7th to 12th grade, no	126	160	143	82	27	538
	18.89	18.96	14.77	11.39	6.82	14.97
High school graduate	145	177	189	112	69	692
	21.74	20.97	19.52	15.56	17.42	19.25
Technical or vocation	36	38	48	36	26	184
	5.40	4.50	4.96	5.00	6.57	5.12
Some college educatio	162	224	228	192	112	918
	24.29	26.54	23.55	26.67	28.28	25.54
College graduate	106	146	188	172	82	694
	15.89	17.30	19.42	23.89	20.71	19.30
Professional or gradu	65	84	162	122	76	509
	9.75	9.95	16.74	16.94	19.19	14.16
Total	667	844	968	720	396	3,595
	100.00	100.00	100.00	100.00	100.00	100.00

Pearson chi2(24) = 135.7751 Pr = 0.000

. tab smokenow egfr_roche_cat_baseline, col chi

```

+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+

```

Current Smoker	egfr_roche_cat_baseline					Total
	1	2	3	4	5	
Not current smoker	557	721	851	636	343	3,108
	83.51	85.43	87.91	88.33	86.40	86.43
Yes current smoker	110	123	117	84	54	488
	16.49	14.57	12.09	11.67	13.60	13.57
Total	667	844	968	720	397	3,596
	100.00	100.00	100.00	100.00	100.00	100.00

Pearson chi2(4) = 9.6190 Pr = 0.047

. tab smoke100 egfr_roche_cat_baseline, col chi

```

+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+

```

Smoked 100 Cigarettes	egfr_roche_cat_baseline					Total
	1	2	3	4	5	
Non-Smoker	262 39.28	344 40.76	426 44.01	345 47.92	208 52.39	1,585 44.08
Smoker	405 60.72	500 59.24	542 55.99	375 52.08	189 47.61	2,011 55.92
Total	667 100.00	844 100.00	968 100.00	720 100.00	397 100.00	3,596 100.00

Pearson chi2(4) = 25.4434 Pr = 0.000

. tab hypertension egfr_roche_cat_baseline, col chi

```

+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+

```

Hypertension (y/n)	egfr_roche_cat_baseline					Total
	1	2	3	4	5	
No	55 8.25	77 9.12	120 12.40	132 18.36	130 32.75	514 14.30
Yes	612 91.75	767 90.88	848 87.60	587 81.64	267 67.25	3,081 85.70
Total	667 100.00	844 100.00	968 100.00	719 100.00	397 100.00	3,596 100.00

Pearson chi2(4) = 161.1733 Pr = 0.000

. tab diabetes_at_baseline egfr_roche_cat_baseline, col chi

```

+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+

```

Diabetes at baseline	egfr_roche_cat_baseline					Total
	1	2	3	4	5	
No diabetes	315 47.23	385 45.62	520 53.72	430 59.72	267 67.25	1,917 53.31
Diabetes	352 52.77	459 54.38	448 46.28	290 40.28	130 32.75	1,679 46.69
Total	667 100.00	844 100.00	968 100.00	720 100.00	397 100.00	3,596 100.00

Pearson chi2(4) = 72.9630 Pr = 0.000

. tab mirevasc egfr_roche_cat_baseline, col chi

```
+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+
```

Myocardial Infarction /Prior Revasc (Y/N)	egfr_roche_cat_baseline					Total
	1	2	3	4	5	
No	497 74.51	617 73.10	741 76.55	589 81.81	346 87.15	2,790 77.59
Yes	170 25.49	227 26.90	227 23.45	131 18.19	51 12.85	806 22.41
Total	667 100.00	844 100.00	968 100.00	720 100.00	397 100.00	3,596 100.00

Pearson chi2(4) = 42.2385 Pr = 0.000

. tab chf egfr_roche_cat_baseline, col chi

```
+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+
```

Congestive Heart Failure (Y/N)	egfr_roche_cat_baseline					Total
	1	2	3	4	5	
No	570 85.46	741 87.80	877 90.60	677 94.03	378 95.21	3,243 90.18
Yes	97 14.54	103 12.20	91 9.40	43 5.97	19 4.79	353 9.82
Total	667 100.00	844 100.00	968 100.00	720 100.00	397 100.00	3,596 100.00

Pearson chi2(4) = 45.8200 Pr = 0.000

. tab pvd egfr_roche_cat_baseline, col chi

```
+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+
```

Peripheral Vascular Disease (Y/N)	egfr_roche_cat_baseline					Total
	1	2	3	4	5	
No	592 88.76	759 89.93	921 95.14	689 95.69	386 97.23	3,347 93.08

Yes	75	85	47	31	11	249
	11.24	10.07	4.86	4.31	2.77	6.92
Total	667	844	968	720	397	3,596
	100.00	100.00	100.00	100.00	100.00	100.00

Pearson chi2(4) = 56.9999 Pr = 0.000

. by egfr_roche_cat_baseline, sort: summarize systolic

-> egfr_roche_cat_baseline = 1

Variable	Obs	Mean	Std. Dev.	Min	Max
systolic	664	130.4779	23.556	72.67	230.67

-> egfr_roche_cat_baseline = 2

Variable	Obs	Mean	Std. Dev.	Min	Max
systolic	842	129.3896	23.18014	76.67	242.67

-> egfr_roche_cat_baseline = 3

Variable	Obs	Mean	Std. Dev.	Min	Max
systolic	966	127.697	21.31851	74.67	214

-> egfr_roche_cat_baseline = 4

Variable	Obs	Mean	Std. Dev.	Min	Max
systolic	716	125.4312	20.16179	77.33	209.33

-> egfr_roche_cat_baseline = 5

Variable	Obs	Mean	Std. Dev.	Min	Max
systolic	395	123.5083	19.98082	80	213.33

-> egfr_roche_cat_baseline = .

Variable	Obs	Mean	Std. Dev.	Min	Max
systolic	15	124.4893	12.63339	106.67	143.33

. oneway systolic egfr_roche_cat_baseline

Source	Analysis of Variance				
	SS	df	MS	F	Prob > F
Between groups	18153.6982	4	4538.42455	9.52	0.0000
Within groups	1706289.72	3578	476.883657		

Total 1724443.42 3582 481.419158

Bartlett's test for equal variances: chi2(4) = 29.8403 Prob>chi2 = 0.000

. by egfr_roche_cat_baseline, sort: summarize diastolic

-> egfr_roche_cat_baseline = 1

Variable	Obs	Mean	Std. Dev.	Min	Max
diastolic	663	69.91605	13.31307	40	116

-> egfr_roche_cat_baseline = 2

Variable	Obs	Mean	Std. Dev.	Min	Max
diastolic	839	70.05533	12.61127	34	122

-> egfr_roche_cat_baseline = 3

Variable	Obs	Mean	Std. Dev.	Min	Max
diastolic	965	71.50181	12.69608	36	118

-> egfr_roche_cat_baseline = 4

Variable	Obs	Mean	Std. Dev.	Min	Max
diastolic	716	72.29468	12.34709	35.33	138.67

-> egfr_roche_cat_baseline = 5

Variable	Obs	Mean	Std. Dev.	Min	Max
diastolic	395	74.85734	12.8442	43.33	138.67

-> egfr_roche_cat_baseline = .

Variable	Obs	Mean	Std. Dev.	Min	Max
diastolic	15	69.86733	11.12421	48	88.67

. oneway diastolic egfr_roche_cat_baseline

Analysis of Variance					
Source	SS	df	MS	F	Prob > F
Between groups	8281.66138	4	2070.41534	12.75	0.0000
Within groups	579999.796	3573	162.328518		
Total	588281.457	3577	164.462247		

Bartlett's test for equal variances: chi2(4) = 4.2591 Prob>chi2 = 0.372

```
. by egfr_roche_cat_baseline, sort: summarize map
```

```
-> egfr_roche_cat_baseline = 1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
map	663	90.09217	14.43721	56.44333	145.9967

```
-> egfr_roche_cat_baseline = 2
```

Variable	Obs	Mean	Std. Dev.	Min	Max
map	839	89.84727	13.96111	56.66667	154.67

```
-> egfr_roche_cat_baseline = 3
```

Variable	Obs	Mean	Std. Dev.	Min	Max
map	965	90.221	13.69512	58.22333	144.22

```
-> egfr_roche_cat_baseline = 4
```

Variable	Obs	Mean	Std. Dev.	Min	Max
map	716	90.00685	13.06242	53.78	161.78

```
egfr_roche_cat_baseline = 5
```

Variable	Obs	Mean	Std. Dev.	Min	Max
map	395	91.07431	13.74467	58.00333	160.4467

```
-> egfr_roche_cat_baseline = .
```

Variable	Obs	Mean	Std. Dev.	Min	Max
map	15	88.07467	10.38735	67.55667	105.1133

```
. oneway map egfr_roche_cat_baseline
```

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	435.693232	4	108.923308	0.57	0.6818
Within groups	678554.83	3573	189.911791		
Total	678990.523	3577	189.821225		

```
Bartlett's test for equal variances: chi2(4) = 7.2754 Prob>chi2 = 0.122
```

```
. tab hibp egfr_roche_cat_baseline, col chi
```

```
+-----+
| Key   |
+-----+
| frequency |
| column percentage |
+-----+
```

High Blood Pressure (Binary)	1	2	3	4	5	Total
egfr_roche_cat_baseline						

	No	Yes	Total	329	448	877	500	397	897	231	1,905
				49.55	53.21	51.76	55.45	58.48			53.17
	Yes			50.45	46.79	48.24	44.55	41.52			46.83
	Total			100.00	100.00	100.00	100.00	100.00			100.00
				664	842	966	716	395			3,583
				100.00	100.00	100.00	100.00	100.00			100.00

Pearson chi2(4) = 10.2354 Pr = 0.037

. by egfr_roche_cat_baseline, sort: summarize weight

-> egfr_roche_cat_baseline = 1

Variable	Obs	Mean	Std. Dev.	Min	Max
weight	665	89.80421	24.7871	39.6	206.6

-> egfr_roche_cat_baseline = 2

Variable	Obs	Mean	Std. Dev.	Min	Max
weight	842	92.25629	23.21441	42.4	195.4

-> egfr_roche_cat_baseline = 3

Variable	Obs	Mean	Std. Dev.	Min	Max
weight	968	92.46322	23.31467	32.4	195.1

-> egfr_roche_cat_baseline = 4

Variable	Obs	Mean	Std. Dev.	Min	Max
weight	720	93.27681	24.10712	40.2	220.9

-> egfr_roche_cat_baseline = 5

Variable	Obs	Mean	Std. Dev.	Min	Max
weight	396	92.25581	22.62912	45.8	199.4

-> egfr_roche_cat_baseline = .

Variable	Obs	Mean	Std. Dev.	Min	Max
weight	15	81.78667	23.4833	41.4	123.9

. oneway weight egfr_roche_cat_baseline

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	4654.94245	4	1163.73561	2.08	0.0809
Within groups	2006939.49	3586	559.659646		
Total	2011594.43	3590	560.332711		

Bartlett's test for equal variances: chi2(4) = 6.0107 Prob>chi2 = 0.198

```
. by egfr_roche_cat_baseline, sort: summarize bmi
```

```
-----
-> egfr_roche_cat_baseline = 1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	664	31.94433	8.410831	16.37499	71.31998

```
-----
-> egfr_roche_cat_baseline = 2
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	841	32.48462	7.89488	15.99768	73.61679

```
-----
-> egfr_roche_cat_baseline = 3
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	967	32.11245	7.768368	14.59011	73.75553

```
-----
-> egfr_roche_cat_baseline = 4
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	719	32.16727	8.13318	14.97431	88.01366

```
-----
-> egfr_roche_cat_baseline = 5
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	396	31.31615	7.065164	18.00297	61.13496

```
-----
-> egfr_roche_cat_baseline = .
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	15	29.11659	7.928544	14.84456	44.90711

```
. oneway bmi egfr_roche_cat_baseline
```

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	386.96996	4	96.7424899	1.54	0.1873
Within groups	224765.936	3582	62.748726		
Total	225152.906	3586	62.7866443		

```
Bartlett's test for equal variances: chi2(4) = 16.3067 Prob>chi2 = 0.003
```

```
. bysort bmi_cat_2: summarize bmi
```

```
-----
-> bmi_cat_2 = 1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	597	22.44584	2.023514	14.59011	24.99901

```
-----
-> bmi_cat_2 = 2
```

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	1018	27.62509	1.408869	25.00499	29.99784

-> bmi_cat_2 = 3

Variable	Obs	Mean	Std. Dev.	Min	Max
bmi	1987	37.25568	6.83807	30.0073	88.01366

. label define bmi_cat_2 1"<25" 2"25-30" 3">30"

. label values bmi_cat_2 bmi_cat_2

. tab bmi_cat_2, missing

BMI Category 2	Freq.	Percent	Cum.
<25	607	16.81	16.81
25-30	1,018	28.18	44.99
>30	1,987	55.01	100.00
Total	3,612	100.00	

. tab bmi_cat_2 egfr_roche_cat_baseline, col chi

```

+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+

```

BMI Category 2	egfr_roche_cat_baseline					Total
	1	2	3	4	5	
<25	132	126	149	121	73	601
	19.79	14.93	15.39	16.81	18.39	16.71
25-30	182	238	275	207	112	1,014
	27.29	28.20	28.41	28.75	28.21	28.20
>30	353	480	544	392	212	1,981
	52.92	56.87	56.20	54.44	53.40	55.09
Total	667	844	968	720	397	3,596
	100.00	100.00	100.00	100.00	100.00	100.00

Pearson chi2(8) = 8.8867 Pr = 0.352

. tab abicat egfr_roche_cat_baseline, col chi

```

+-----+
| Key |
+-----+
| frequency |
| column percentage |
+-----+

```

Lowest ABI	egfr_roche_cat_baseline					Total
	1	2	3	4	5	
<0.9	501	663	813	615	374	2,966
	76.37	80.07	85.04	85.89	95.41	83.60

<0.9	155	165	143	101	18	582
	23.63	19.93	14.96	14.11	4.59	16.40

Total	656	828	956	716	392	3,548
	100.00	100.00	100.00	100.00	100.00	100.00

Pearson chi2(4) = 76.5620 Pr = 0.000

```
. by egfr_roche_cat_baseline, sort: summarize scr_roche
```

```
-----
```

```
-> egfr_roche_cat_baseline = 1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
scr_roche	667	2.561627	.5579704	1.70754	7.85751

```
-----
```

```
-> egfr_roche_cat_baseline = 2
```

Variable	Obs	Mean	Std. Dev.	Min	Max
scr_roche	844	1.901166	.3245337	1.35102	3.705

```
-----
```

```
-> egfr_roche_cat_baseline = 3
```

Variable	Obs	Mean	Std. Dev.	Min	Max
scr_roche	968	1.557905	.2329289	1.08363	2.24232

```
-----
```

```
-> egfr_roche_cat_baseline = 4
```

Variable	Obs	Mean	Std. Dev.	Min	Max
scr_roche	720	1.315606	.196654	.9945	1.79667

```
-----
```

```
-> egfr_roche_cat_baseline = 5
```

Variable	Obs	Mean	Std. Dev.	Min	Max
scr_roche	397	1.13841	.2034862	.54885	1.61841

```
-----
```

```
-> egfr_roche_cat_baseline = .
```

Variable	Obs	Mean	Std. Dev.	Min	Max
scr_roche	0				

```
. oneway scr_roche egfr_roche_cat_baseline
```

Analysis of Variance					
Source	SS	df	MS	F	Prob > F
Between groups	777.277302	4	194.319325	1776.47	0.0000
Within groups	392.801103	3591	.10938488		
Total	1170.0784	3595	.325473826		

Bartlett's test for equal variances: chi2(4) = 1.1e+03 Prob>chi2 = 0.000

```
. by egfr_roche_cat_baseline, sort: summarize UPROTEIN24H, detail
```

-> egfr_roche_cat_baseline = 1

24H Urine Protein (g/24H)

	Percentiles	Smallest		
1%	.0225271	.0159446		
5%	.048096	.0173196		
10%	.06075	.0178054	Obs	624
25%	.1447146	.0196129	Sum of Wgt.	624
50%	.5748		Mean	1.688951
		Largest	Std. Dev.	2.827729
75%	2.1445	17.313		
90%	4.368	17.7375	Variance	7.996049
95%	6.956	18.90536	Skewness	3.363272
99%	15.9495	20.10376	Kurtosis	16.93411

-> egfr_roche_cat_baseline = 2

24H Urine Protein (g/24H)

	Percentiles	Smallest		
1%	.0234	.01275		
5%	.03675	.0138		
10%	.048	.0188509	Obs	806
25%	.0818919	.0189	Sum of Wgt.	806
50%	.2620408		Mean	1.187282
		Largest	Std. Dev.	2.517357
75%	1.222	15.8556		
90%	3.04	16.766	Variance	6.337087
95%	5.155944	23.8038	Skewness	5.115506
99%	12.73845	30.11958	Kurtosis	40.43512

-> egfr_roche_cat_baseline = 3

24H Urine Protein (g/24H)

	Percentiles	Smallest		
1%	.0195392	.013		
5%	.0309221	.0145895		
10%	.042	.0171089	Obs	932
25%	.0668538	.0173847	Sum of Wgt.	932
50%	.1345824		Mean	.8092481
		Largest	Std. Dev.	1.931273
75%	.6006621	14.82		
90%	2.173	16.0775	Variance	3.729816
95%	3.870955	17.52338	Skewness	5.091695
99%	9.652	21.528	Kurtosis	37.19655

-> egfr_roche_cat_baseline = 4

24H Urine Protein (g/24H)

	Percentiles	Smallest		
1%	.02025	.0159319		
5%	.035234	.0161739		
10%	.0441191	.0169412	Obs	684
25%	.0646852	.0171	Sum of Wgt.	684
50%	.102		Mean	.5658374
		Largest	Std. Dev.	1.485828
75%	.3561429	8.4643		
90%	1.249032	10.5773	Variance	2.207685

```

95%      2.728      12.342      Skewness      6.416126
99%      8.024361   20.05677   Kurtosis      60.89227

```

```
-----
-> egfr_roche_cat_baseline = 5
```

24H Urine Protein (g/24H)

```
-----
Percentiles      Smallest
1%      .024      .0076755
5%      .0341053   .017
10%     .0453147   .0213      Obs      368
25%     .062809   .024      Sum of Wgt.  368

50%     .0995751

Largest      Mean      .3883365
4.238001     Std. Dev. .9474327
75%     .2203573   4.238001
90%     1.0112     4.4928     Variance   .8976287
95%     1.916229   7.8144     Skewness   5.930934
99%     4.238001   10.512    Kurtosis   50.39896

```

```
-----
-> egfr_roche_cat_baseline = .
```

24H Urine Protein (g/24H)

```
-----
Percentiles      Smallest
1%      .0426667   .0426667
5%      .0426667   .0704
10%     .0565333   .0805      Obs      10
25%     .0805     .0984558   Sum of Wgt.  10

50%     .2812

Largest      Mean      .7259476
1.08         Std. Dev. .839891
75%     1.102     1.08
90%     2.111527   1.102     Variance   .7054168
95%     2.304     1.919054   Skewness   .8590172
99%     2.304     2.304     Kurtosis   2.27084

```

```
. oneway UPROTEIN24H egfr_roche_cat_baseline
```

```

Analysis of Variance
Source          SS          df          MS          F          Prob > F
-----
Between groups  620.831902    4    155.207976   34.37    0.0000
Within groups  15392.6303  3409    4.51529196
-----
Total          16013.4622  3413    4.69190219

```

```
Bartlett's test for equal variances:  chi2(4) = 630.2099  Prob>chi2 = 0.000
```

```
. label values acearb YESNO
```

```
. tab acearb egfr_roche_cat_baseline, col chi
```

```

+-----+
| Key |
|-----|
| frequency |
| column percentage |
+-----+

```

```

ACE inh or |          egfr_roche_cat_baseline
ARB |          1          2          3          4          5 |          Total
-----+-----
No |          220          221          267          240          195 |          1,143
|          32.98          26.18          27.58          33.33          49.12 |          31.79

```

	Yes	623	701	480	202	2,453
	447	73.82	72.42	66.67	50.88	68.21
Total	667	844	968	720	397	3,596
	100.00	100.00	100.00	100.00	100.00	100.00

Pearson chi2(4) = 76.3414 Pr = 0.000

. by egfr_roche_cat_baseline, sort: summarize tc

-> egfr_roche_cat_baseline = 1

Variable	Obs	Mean	Std. Dev.	Min	Max
tc	667	183.3328	51.5675	79	571

-> egfr_roche_cat_baseline = 2

Variable	Obs	Mean	Std. Dev.	Min	Max
tc	844	182.5166	46.33621	80	512

-> egfr_roche_cat_baseline = 3

Variable	Obs	Mean	Std. Dev.	Min	Max
tc	968	183.2965	42.09724	76	370

-> egfr_roche_cat_baseline = 4

Variable	Obs	Mean	Std. Dev.	Min	Max
tc	720	183.1778	41.20084	77	350

-> egfr_roche_cat_baseline = 5

Variable	Obs	Mean	Std. Dev.	Min	Max
tc	397	183.5164	39.2484	88	344

-> egfr_roche_cat_baseline = .

Variable	Obs	Mean	Std. Dev.	Min	Max
tc	6	144.5	31.45632	97	184

. oneway tc egfr_roche_cat_baseline

Analysis of Variance					
Source	SS	df	MS	F	Prob > F
Between groups	432.445893	4	108.111473	0.05	0.9945
Within groups	7125209.17	3591	1984.18523		
Total	7125641.62	3595	1982.09781		

Bartlett's test for equal variances: chi2(4) = 60.1577 Prob>chi2 = 0.000

. by egfr_roche_cat_baseline, sort: summarize ldl

-> egfr_roche_cat_baseline = 1

Variable	Obs	Mean	Std. Dev.	Min	Max
ldl	665	99.94436	38.61337	16	295

-> egfr_roche_cat_baseline = 2

Variable	Obs	Mean	Std. Dev.	Min	Max
ldl	843	100.4128	35.6319	21	242

-> egfr_roche_cat_baseline = 3

Variable	Obs	Mean	Std. Dev.	Min	Max
ldl	968	103.3432	34.81021	25	232

-> egfr_roche_cat_baseline = 4

Variable	Obs	Mean	Std. Dev.	Min	Max
ldl	718	104.468	33.23696	15	250

-> egfr_roche_cat_baseline = 5

Variable	Obs	Mean	Std. Dev.	Min	Max
ldl	397	107.2363	32.58035	28	243

-> egfr_roche_cat_baseline = .

Variable	Obs	Mean	Std. Dev.	Min	Max
ldl	6	74.16667	20.93243	52	110

. oneway ldl egfr_roche_cat_baseline

Analysis of Variance					
Source	SS	df	MS	F	Prob > F
Between groups	20272.4348	4	5068.10869	4.09	0.0026
Within groups	4443225.16	3586	1239.04773		
Total	4463497.59	3590	1243.31409		

Bartlett's test for equal variances: chi2(4) = 21.6367 Prob>chi2 = 0.000

. by egfr_roche_cat_baseline, sort: summarize hdl

-> egfr_roche_cat_baseline = 1

Variable	Obs	Mean	Std. Dev.	Min	Max
hdl	667	46.73463	15.50637	8	117

-> egfr_roche_cat_baseline = 2

Variable	Obs	Mean	Std. Dev.	Min	Max
----------	-----	------	-----------	-----	-----

```
-----+-----
      hdl |      844   47.37204   15.73005      15      162
-----+-----
```

```
-> egfr_roche_cat_baseline = 3
```

```
Variable |      Obs      Mean   Std. Dev.      Min      Max
-----+-----
      hdl |      968   48.17355   14.82992      12     140
-----+-----
```

```
-> egfr_roche_cat_baseline = 4
```

```
Variable |      Obs      Mean   Std. Dev.      Min      Max
-----+-----
      hdl |      720   48.81806   15.9736      12     170
-----+-----
```

```
-> egfr_roche_cat_baseline = 5
```

```
Variable |      Obs      Mean   Std. Dev.      Min      Max
-----+-----
      hdl |      397   50.17632   16.42642      23     118
-----+-----
```

```
-> egfr_roche_cat_baseline = .
```

```
Variable |      Obs      Mean   Std. Dev.      Min      Max
-----+-----
      hdl |         6   41.16667   11.8223      23      55
-----+-----
```

```
. oneway  hdl  egfr_roche_cat_baseline
```

Analysis of Variance					
Source	SS	df	MS	F	Prob > F
Between groups	3775.15844	4	943.78961	3.89	0.0037
Within groups	871702.876	3591	242.746554		
Total	875478.034	3595	243.526574		

```
Bartlett's test for equal variances:  chi2(4) = 7.9453  Prob>chi2 = 0.094
```

```
. by egfr_roche_cat_baseline, sort: summarize tg
```

```
-> egfr_roche_cat_baseline = 1
```

```
Variable |      Obs      Mean   Std. Dev.      Min      Max
-----+-----
      tg |      667   167.7856   126.7914      35     1509
-----+-----
```

```
-> egfr_roche_cat_baseline = 2
```

```
Variable |      Obs      Mean   Std. Dev.      Min      Max
-----+-----
      tg |      844   162.3306   122.9593      33     1593
-----+-----
```

```
-> egfr_roche_cat_baseline = 3
```

```
Variable |      Obs      Mean   Std. Dev.      Min      Max
-----+-----
      tg |      968   150.7562   98.98185      31     827
-----+-----
```

-> egfr_roche_cat_baseline = 4

Variable	Obs	Mean	Std. Dev.	Min	Max
tg	720	148.2597	127.4205	38	1755

-> egfr_roche_cat_baseline = 5

Variable	Obs	Mean	Std. Dev.	Min	Max
tg	397	128.6096	81.51347	31	639

-> egfr_roche_cat_baseline = .

Variable	Obs	Mean	Std. Dev.	Min	Max
tg	6	155.1667	91.46675	76	293

. oneway tg egfr_roche_cat_baseline

Analysis of Variance					
Source	SS	df	MS	F	Prob > F
Between groups	474823.302	4	118705.826	9.03	0.0000
Within groups	47230922.5	3591	13152.5821		
Total	47705745.8	3595	13270.0266		

Bartlett's test for equal variances: chi2(4) = 152.5291 Prob>chi2 = 0.000

. by egfr_roche_cat_baseline, sort: summarize CBCHemoglobin

-> egfr_roche_cat_baseline = 1

Variable	Obs	Mean	Std. Dev.	Min	Max
CBCHemoglo~n	661	11.84221	1.691732	5.3	18.9

-> egfr_roche_cat_baseline = 2

Variable	Obs	Mean	Std. Dev.	Min	Max
CBCHemoglo~n	838	12.30955	1.696656	7.1	18

-> egfr_roche_cat_baseline = 3

Variable	Obs	Mean	Std. Dev.	Min	Max
CBCHemoglo~n	959	12.79176	1.717844	8.1	18.9

-> egfr_roche_cat_baseline = 4

Variable	Obs	Mean	Std. Dev.	Min	Max
CBCHemoglo~n	716	13.24162	1.637216	7.5	18.6

-> egfr_roche_cat_baseline = 5

Variable	Obs	Mean	Std. Dev.	Min	Max
----------	-----	------	-----------	-----	-----

```
CBCHemoglo~n |      389    13.44036    1.627452      6.6      17.4
```

```
-----  
-> egfr_roche_cat_baseline = .
```

```
Variable |      Obs      Mean    Std. Dev.    Min      Max  
-----+-----  
CBCHemoglo~n |      7    12.35714    1.926012     9.8     14.8
```

```
. oneway    CBCHemoglobin  egfr_roche_cat_baseline
```

```
Analysis of Variance  
Source          SS          df      MS          F      Prob > F  
-----+-----  
Between groups    1040.69058      4    260.172644    91.93    0.0000  
Within groups    10069.557    3558     2.8301172  
-----+-----  
Total            11110.2476    3562     3.11910375
```

```
Bartlett's test for equal variances:  chi2(4) = 2.8810  Prob>chi2 = 0.578
```

```
.  
. by egfr_roche_cat_baseline, sort: summarize calcium
```

```
-----  
-> egfr_roche_cat_baseline = 1
```

```
Variable |      Obs      Mean    Std. Dev.    Min      Max  
-----+-----  
calcium |     667    9.107346    .5676647     6.3     11.7
```

```
-----  
-> egfr_roche_cat_baseline = 2
```

```
Variable |      Obs      Mean    Std. Dev.    Min      Max  
-----+-----  
calcium |     842    9.206413    .5041862     7.2     10.9
```

```
-----  
-> egfr_roche_cat_baseline = 3
```

```
Variable |      Obs      Mean    Std. Dev.    Min      Max  
-----+-----  
calcium |     963    9.234579    .4824342     6.9     11.3
```

```
-----  
-> egfr_roche_cat_baseline = 4
```

```
Variable |      Obs      Mean    Std. Dev.    Min      Max  
-----+-----  
calcium |     712    9.219522    .4884008     5.8     11.1
```

```
-----  
-> egfr_roche_cat_baseline = 5
```

```
Variable |      Obs      Mean    Std. Dev.    Min      Max  
-----+-----  
calcium |     395    9.213671    .4207383     6.7     10.3
```

```
-----  
-> egfr_roche_cat_baseline = .
```

```
Variable |      Obs      Mean    Std. Dev.    Min      Max  
-----+-----  
calcium |      2      9.05    .7778175     8.5     9.6
```

```
. oneway    calcium  egfr_roche_cat_baseline
```

Analysis of Variance					
Source	SS	df	MS	F	Prob > F
Between groups	7.25327466	4	1.81331866	7.27	0.0000
Within groups	891.642691	3574	.249480328		
Total	898.895965	3578	.25122861		

Bartlett's test for equal variances: $\chi^2(4) = 47.6409$ Prob> $\chi^2 = 0.000$

. by egfr_roche_cat_baseline, sort: summarize phosphate

-> egfr_roche_cat_baseline = 1

Variable	Obs	Mean	Std. Dev.	Min	Max
phosphate	658	4.119909	.7788971	1.9	9.3

-> egfr_roche_cat_baseline = 2

Variable	Obs	Mean	Std. Dev.	Min	Max
phosphate	834	3.792326	.6145797	1.8	6.4

-> egfr_roche_cat_baseline = 3

Variable	Obs	Mean	Std. Dev.	Min	Max
phosphate	958	3.596242	.5749076	2.1	5.8

-> egfr_roche_cat_baseline = 4

Variable	Obs	Mean	Std. Dev.	Min	Max
phosphate	708	3.506215	.5646501	1.7	6.6

-> egfr_roche_cat_baseline = 5

Variable	Obs	Mean	Std. Dev.	Min	Max
phosphate	388	3.438918	.5228681	2	5.1

-> egfr_roche_cat_baseline = .

Variable	Obs	Mean	Std. Dev.	Min	Max
phosphate	3	4.133333	.2886751	3.8	4.3

. oneway phosphate egfr_roche_cat_baseline

Analysis of Variance					
Source	SS	df	MS	F	Prob > F
Between groups	186.411565	4	46.6028912	121.27	0.0000
Within groups	1360.74155	3541	.384281715		
Total	1547.15312	3545	.436432474		

Bartlett's test for equal variances: $\chi^2(4) = 122.2974$ Prob> $\chi^2 = 0.000$

```
. by egfr_roche_cat_baseline, sort: summarize TOTAL_PTH
```

```
-----
-> egfr_roche_cat_baseline = 1
```

Variable	Obs	Mean	Std. Dev.	Min	Max
TOTAL_PTH	640	132.3241	102.7773	8.2	741

```
-----
-> egfr_roche_cat_baseline = 2
```

Variable	Obs	Mean	Std. Dev.	Min	Max
TOTAL_PTH	823	82.94982	83.10112	1.9	1483

```
-----
-> egfr_roche_cat_baseline = 3
```

Variable	Obs	Mean	Std. Dev.	Min	Max
TOTAL_PTH	939	60.49329	44.69337	3	383

```
-----
-> egfr_roche_cat_baseline = 4
```

Variable	Obs	Mean	Std. Dev.	Min	Max
TOTAL_PTH	704	48.59091	28.88493	7.9	209.2

```
-----
-> egfr_roche_cat_baseline = 5
```

Variable	Obs	Mean	Std. Dev.	Min	Max
TOTAL_PTH	385	41.73792	23.63179	6.9	230.4

```
-----
-> egfr_roche_cat_baseline = .
```

Variable	Obs	Mean	Std. Dev.	Min	Max
TOTAL_PTH	4	64.05	48.21856	12.9	108

```
. oneway TOTAL_PTH egfr_roche_cat_baseline
```

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	3268722.83	4	817180.708	188.64	0.0000
Within groups	15101072.4	3486	4331.91981		
Total	18369795.3	3490	5263.55165		

```
Bartlett's test for equal variances: chi2(4) = 1.7e+03 Prob>chi2 = 0.000
```

```
.
. * NOTE this is INACTIVE
. * by egfr_roche_cat_baseline, sort: summarize cip_value, detail
. * oneway cip_value egfr_roche_cat_baseline
.
. by egfr_roche_cat_baseline, sort: summarize glucose, detail
```

```
-----
-> egfr_roche_cat_baseline = 1
```

```
GLUCOSE (mg/dL)
```


	Percentiles	Smallest		
1%	62	36		
5%	72	43		
10%	76	48	Obs	666
25%	85	56	Sum of Wgt.	666
50%	96.5		Mean	114.9249
		Largest	Std. Dev.	53.88613
75%	124	362		
90%	173	447	Variance	2903.715
95%	216	519	Skewness	3.125742
99%	341	522	Kurtosis	17.29345

-> egfr_roche_cat_baseline = 2

GLUCOSE (mg/dL)

	Percentiles	Smallest		
1%	58	42		
5%	71	43		
10%	78	47	Obs	841
25%	87	47	Sum of Wgt.	841
50%	98		Mean	118.8787
		Largest	Std. Dev.	57.43109
75%	131	399		
90%	191	450	Variance	3298.331
95%	236	487	Skewness	2.77753
99%	325	596	Kurtosis	14.41807

-> egfr_roche_cat_baseline = 3

GLUCOSE (mg/dL)

	Percentiles	Smallest		
1%	59	42		
5%	75	42		
10%	81	47	Obs	963
25%	88	49	Sum of Wgt.	963
50%	100		Mean	116.8733
		Largest	Std. Dev.	51.89112
75%	127	428		
90%	177	445	Variance	2692.689
95%	217	492	Skewness	3.155768
99%	312	582	Kurtosis	18.48746

-> egfr_roche_cat_baseline = 4

GLUCOSE (mg/dL)

	Percentiles	Smallest		
1%	59	31		
5%	74	36		
10%	78	43	Obs	711
25%	85	48	Sum of Wgt.	711
50%	95		Mean	109.7117
		Largest	Std. Dev.	44.51902
75%	119	347		
90%	157	397	Variance	1981.944
95%	195	398	Skewness	3.41
99%	268	545	Kurtosis	22.8142

-> egfr_roche_cat_baseline = 5

GLUCOSE (mg/dL)

```
-----
```

Percentiles	Smallest		
1%	58	44	
5%	72	46	
10%	78	51	Obs 396
25%	84	58	Sum of Wgt. 396
50%	94		Mean 107.2045
		Largest	Std. Dev. 44.25966
75%	110	308	
90%	155	333	Variance 1958.918
95%	203	368	Skewness 2.933356
99%	308	377	Kurtosis 13.63301

-> egfr_roche_cat_baseline = .

GLUCOSE (mg/dL)

```
-----
```

Percentiles	Smallest		
1%	79	79	
5%	79	.	
10%	79	.	Obs 1
25%	79	.	Sum of Wgt. 1
50%	79		Mean 79
		Largest	Std. Dev. .
75%	79	.	
90%	79	.	Variance .
95%	79	.	Skewness .
99%	79	79	Kurtosis .

. oneway glucose egfr_roche_cat_baseline

```
-----
```

Source	Analysis of Variance			F	Prob > F
	SS	df	MS		
Between groups	59047.0007	4	14761.7502	5.57	0.0002
Within groups	9472886.74	3572	2651.98397		
Total	9531933.75	3576	2665.52957		

Bartlett's test for equal variances: chi2(4) = 68.2147 Prob>chi2 = 0.000

. by egfr_roche_cat_baseline, sort: summarize HEMOGLOBIN_A1C

-> egfr_roche_cat_baseline = 1

```
-----
```

Variable	Obs	Mean	Std. Dev.	Min	Max
HEMOGLOBI~1C	658	6.666717	1.543021	3.8	14.7

-> egfr_roche_cat_baseline = 2

```
-----
```

Variable	Obs	Mean	Std. Dev.	Min	Max
HEMOGLOBI~1C	826	6.818402	1.636278	3.5	15.2

-> egfr_roche_cat_baseline = 3

```
-----
```

Variable	Obs	Mean	Std. Dev.	Min	Max
HEMOGLOBI~1C	959	6.679458	1.540214	4.2	13.7

-> egfr_roche_cat_baseline = 4

Variable	Obs	Mean	Std. Dev.	Min	Max
HEMOGLOBI~1C	712	6.467556	1.428109	4.1	14.3

-> egfr_roche_cat_baseline = 5

Variable	Obs	Mean	Std. Dev.	Min	Max
HEMOGLOBI~1C	387	6.335917	1.660678	4.4	18.3

-> egfr_roche_cat_baseline = .

Variable	Obs	Mean	Std. Dev.	Min	Max
HEMOGLOBI~1C	4	6.825	.8261356	5.8	7.8

. oneway HEMOGLOBIN_A1C egfr_roche_cat_baseline

Analysis of Variance					
Source	SS	df	MS	F	Prob > F
Between groups	84.8083429	4	21.2020857	8.76	0.0000
Within groups	8560.35802	3537	2.42023127		
Total	8645.16636	3541	2.44144771		

Bartlett's test for equal variances: chi2(4) = 17.9037 Prob>chi2 = 0.001

. by egfr_roche_cat_baseline, sort: summarize URIC_ACID

-> egfr_roche_cat_baseline = 1

Variable	Obs	Mean	Std. Dev.	Min	Max
URIC_ACID	659	8.217147	1.958046	2.2	15.2

-> egfr_roche_cat_baseline = 2

Variable	Obs	Mean	Std. Dev.	Min	Max
URIC_ACID	837	7.90454	1.866349	1.9	14.8

-> egfr_roche_cat_baseline = 3

Variable	Obs	Mean	Std. Dev.	Min	Max
URIC_ACID	959	7.343066	1.77989	2.4	13.3

-> egfr_roche_cat_baseline = 4

Variable	Obs	Mean	Std. Dev.	Min	Max
URIC_ACID	714	6.788235	1.6449	2.7	12.2

-> egfr_roche_cat_baseline = 5

Variable	Obs	Mean	Std. Dev.	Min	Max
----------	-----	------	-----------	-----	-----

```

-----+-----
  URIC_ACID |      392    6.104082    1.653125         2    11.7
-----+-----
-> egfr_roche_cat_baseline = .

  Variable |      Obs      Mean    Std. Dev.      Min      Max
-----+-----
  URIC_ACID |         2      6.35    1.343503      5.4      7.3

. oneway  URIC_ACID egfr_roche_cat_baseline

              Analysis of Variance
  Source              SS          df           MS          F          Prob > F
-----+-----
Between groups    1581.33657         4    395.334143    122.59    0.0000
Within groups    11467.385       3556    3.22479894
-----+-----
Total            13048.7216       3560    3.66537123

Bartlett's test for equal variances:  chi2(4) = 28.5650  Prob>chi2 = 0.000

.
.
end of do-file

. log close
  name: <unnamed>
  log: R:\CRIC\July_2011\MS004\2.log
  log type: text
  closed on: 14 Aug 2011, 08:50:35

```